Anthrax: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis

Last updated April 6, 2009

Agent and Pathogenesis
Epidemiology
Anthrax as a Biological Weapon
Clinical Syndromes and Differential Diagnosis
Clinical Laboratory Testing
Treatment and Postexposure Prophylaxis
Anthrax Vaccination
Management of Exposure Events
Hospital Infection Control (Including Autopsies and Burial)
Environmental Testing and Decontamination
Public Health Reporting and Case Definitions
Images
References

Agent and Pathogenesis

Agent

Key microbiologic characteristics of Bacillus anthracis follow (see References: CDC: Basic laboratory protocol for identification of Bacillus anthracis):

• Vegetative cell: large, gram-positive bacillus (1.0 to 1.5 mcm by 3.0 to 5.0 mcm), "jointed bamboo-rod" appearance
• Endospore: oval, central-to-subterminal, does not usually swell (1.0 x 1.5 mcm); CO₂ levels within the body inhibit sporulation
• Forms long chains of vegetative cells in vitro; single cells or short chains of 2 to 4 cells in direct clinical samples
• Aerobic or facultatively anaerobic
• Nonmotile
• Catalase-positive
• Nonhemolytic on sheep blood agar
• Susceptible to lysis by gamma phage
• Rapid growth on sheep blood agar (SBA); comma-shaped projections may give "Medusa head" appearance on SBA
• Colonies have been described as having a "ground glass" or curled hair" appearance and have the consistency of beaten egg whites
• Colonies are 2 to 5 mm in diameter after 16 to 18 hours of incubation
• Forms mucoid capsule when grown on agar with sodium bicarbonate and incubated in CO₂-enriched atmosphere; capsule can be visualized with India ink preparation

Spores germinate and form vegetative cells in environments rich in nutrients (eg, glucose, amino acids, nucleosides). Vegetative bacteria generally survive poorly outside of mammalian hosts. Conversely, vegetative cells form spores when nutrients in the environment are exhausted. Spores are protected by a morphologically complex protein coat (see References: Giorno 2007). Spores have been shown to have heat-resistance characteristics similar to other Bacillus species, and can survive in the environment for more than 40 years (see References: Manchee 1990, Montville 2005).

Pathogenesis

Virulence factors

The primary virulence factors produced by B anthracis are plasmid-coded and include:

• A poly-D-glutamic acid capsule (coded for on plasmid pX02) that inhibits phagocytosis of vegetative bacilli
• Three exotoxins that combine to produce two binary toxins:
• Protective antigen (PA) is a binding protein, which permits entry of toxin into host cells via endocyte formation. Once in the endocyte, PA toxin forms a pore, which creates a small passageway in the endosomal membrane that allows the enzymatic components of the toxin to enter the cytoplasm.
• Edema factor (EF) is a calmodulin-dependent adenylate cyclase. EF combines with PA to form edema toxin (coded by the cya gene of plasmid pX01).
• Edema toxin converts adenosine triphosphate to cyclic adenosine monophosphate (cAMP); high intracellular levels of cAMP lead to impaired maintenance of water homeostasis and characteristic edema (see References: Kumar 2002).
• Edema toxin also inhibits neutrophil function and stimulates production or release of multiple inflammatory mediators, including neurokinins, prostanoids, and histamine (see References: Tessier 2007).
• Lethal factor (LF) is a zinc metalloprotease. LF combines with PA to form lethal toxin (coded by the lef gene on pX01).
• Lethal toxin is thought to stimulate overproduction of cytokines (eg, tumor necrosis factor [TNF] alpha and interleukin [IL] 1-beta), which leads to lysis of macrophages. Rapid release of inflammatory mediators also may contribute to the sudden death that can occur with anthrax.
• Lethal toxin has been shown to cause endothelial cell apoptosis and endothelial barrier dysfunction, which may contribute to vascular destruction (see References: Kirby 2004, Warfel 2005).

Virulence of B anthracis appears to be related to clonality and to the numbers of copies of the pX01 and PX02 plasmids within each bacterial cell (see References: Coker 2003). The complete genomic sequence of B anthracis (Ames strain) has been analyzed; several chromosomally encoded potential virulence factors were identified, including hemolysin, phospholipases, and iron acquisition proteins (see References: Read 2003).

Anthrax toxin genes were identified in a naturally occurring Bacillus cereus isolate obtained from a patient with an illness similar to inhalational anthrax (see References: Hoffmaster 2004). More recently, anthrax-like illnesses were identified in two metalworkers who had inhalation exposure to B cereus that contained B anthracis toxin genes (see References: Avashia 2007).

Inhalational anthrax

Pathogenesis of inhalational anthrax involves the following steps (see References: Hanna 1998, Abramova 1993):

• Endospores are introduced into the body via inhalation. Endospores are 1 mcm by 1.5 mcm in size (see References: CDC: Basic laboratory protocol for identification of Bacillus anthracis) and are, therefore, able to reach the alveoli (ie, <5 mcm).
• Endospores are phagocytosed by macrophages and carried to regional lymph nodes. They also appear to be taken up by lung epithelial cells (see References: Russell 2008).
• The endospores then germinate inside macrophages and become vegetative cells, which leave the macrophages and multiply in the lymphatic system.
• Bacteria enter the bloodstream and lead to septic shock and toxemia; hematogenous spread can lead to hemorrhagic meningitis.
• Regional hemorrhagic lymphadenitis of mediastinal and peribronchial lymph nodes causes the occurrence of hemorrhagic mediastinitis (see References: Abramova 1993). A widened mediastinum may be noted on chest radiograph or enlarged lymph nodes may be directly visualized on chest computed tomography.
• Pulmonary lymphatic drainage can be blocked, leading to pulmonary edema.
• Pleural effusions are common and may be massive. B anthracis bacilli, bacillary fragments, and antigens can be noted with immunohistochemistry (IHC) testing of pleural effusions (see References: Guarner 2003).
• True pneumonia rarely occurs, although a focal, hemorrhagic, necrotizing pneumonic lesion (similar to the Gohn complex of tuberculosis) may be seen (see References: Abramova 1993). Intraalveolar edema, focal areas of hyaline membrane formation, and interstitial mononuclear inflammation may be noted (see References: Guarner 2003).
• Compression of the lungs and septic shock are the major causes of death.
• The ID₅₀ for inhalational anthrax is estimated at 8,000 to 50,000 spores (see References: Franz 1997), although the minimum infective dose may be considerably less. On the basis of experimental studies involving primates, the US Department of Defense has estimated that the LD₅₀ for inhalational anthrax in humans from weapons-grade anthrax is 2,500 to 55,000 spores (see References: Defense Intelligence Agency).
• Extrapolation of dose-response curves involving cynomolgous monkeys suggest that the LD₁₀ in humans following exposure to airborne anthrax spores may be as low as 50 to 98 spores, the LD₅ may be only 14 to 28 spores, and the LD₁ may be only one to three spores (see References: Peters 2002).
• Mathematical modeling of airborne anthrax infection (based on observations from the US Postal Service experience during the 2001 anthrax outbreak and an assumption that 10,000 people may have been exposed) suggests that exposures ranged from 18 to 863 spores and may have been as low as 2 to 9 spores (see References: Fennelly 2004).
• Animal data have suggested that anthrax spores might be able to survive in the lungs for longer than 60 days; in one study, live spores were detected in the lymph nodes of a monkey 100 days after exposure (see References: Henderson 1956).

Cutaneous anthrax

The pathogenesis of cutaneous anthrax involves the following process:

• Endospores are introduced through the skin (usually via preexisting skin lesions or abrasions).
• Low-level germination at the site of introduction produces localized necrosis with eschar formation and soft-tissue or mucosal edema (which can be massive in some cases). Epithelial damage appears to be required for germination of spores. Germination begins 1 to 3 hours after inoculation, but spore germination by itself is not sufficient to produce infection in undamaged skin (see References: Bischof 2007).
• Endospores often are phagocytosed by macrophages and carried to regional lymph nodes, causing painful lymphadenopathy and lymphangitis.
• Hematogenous spread with resultant toxemia can occur, although such spread is not common with appropriate antibiotic therapy.
• The infective dose for cutaneous anthrax is not known.

Gastrointestional anthrax

The pathogenesis of gastrointestinal anthrax is not clear, since this condition is relatively rare. Historically, illness has been thought to result from ingestion of B anthracis spores; however, recently experts have postulated that illness predominantly results from ingestion of large numbers of vegetative cells (such as may be found in poorly cooked meat from infected animals) (see References: Inglesby 2002).

• Two forms of gastrointestinal anthrax have been recognized: oropharyngeal and gastrointestinal.
• In oropharyngeal anthrax, the portal of entry is the oral or pharyngeal mucosa. A mucosal ulcer occurs initially, followed by regional lymphadenopathy and localized edema.
• In gastrointestinal anthrax, the portal of entry often is the terminal ileum or cecum. Intestinal lesions occur and are followed by regional lymphadenopathy. Edema of the bowel wall and ascites (sometimes massive) may be present.
• Hematogenous spread with resultant toxemia can occur.
• The infective dose for gastrointestinal anthrax is not known. In animal models (guinea pigs, rabbits, and rhesus monkeys), investigators failed to induce infection following oral challenge with 10⁸ spores; these animals are all thought to be more susceptible to anthrax than humans (see References: Beatty 2003).

Back to top

Epidemiology

Reservoir

B anthracis is found in soil in many areas of the world. Ecologic factors (such as abundant rainfall following a period of drought) may enhance spore density in soil, although the exact influence of such factors remains poorly understood.

The organism generally exists in the endospore form in nature; germination of spores outside an animal host may occur when the following conditions are met (see References: Turnbull 1998):

• Temperature between 8°C and 45°C
• pH between 5 and 9
• Relative humidity >95%
• Presence of adequate nutrients

Endospores are resistant to drying, heat, ultraviolet light, gamma radiation, and some disinfectants. Spores can persist in soil for decades, as illustrated by biological warfare experiments during World War II on the Scottish island of Gruinard (see References: Manchee 1990). During 1943 and 1944, an estimated 4 x 10¹⁴ anthrax spores were dispersed on the island through explosive means. Spores were still detectable more than 40 years later. Disinfection of the island was finally completed in 1987, using a combination of seawater and formaldehyde.

Anthrax in Animals

Anthrax is predominantly a disease of livestock. Livestock or other herbivores (eg, cattle, sheep, goats, pigs, bison, water buffalo) acquire infection from consuming contaminated soil or feed. Anthrax in animals is hyperendemic or endemic in the following areas of the world (see References: WHOCC):

• Most areas of the Middle East
• Most areas of equatorial Africa
• Mexico and Central America
• Chile, Argentina, Peru, and Bolivia
• Certain Southeast Asian countries (eg, Myanmar, Vietnam, Cambodia, Thailand)
• Papua New Guinea
• China
• Some Mediterranean countries

In most of the rest of the world, anthrax occurs only sporadically. In the United States, outbreaks in animals have occurred since 1990 in the Midwest (Kansas, Minnesota, Nebraska, North Dakota, South Dakota, Missouri); in the West (California, Nevada); and in Texas and Oklahoma (see References: WHOCC; MBAH 2006). Outbreaks have also recently occurred in Saskatchewan and Manitoba, Canada, affecting more than 930 animals (see References: CFIA 2006).

Anthrax has been reported as the cause of death among chimpanzees in Ivory Coast (see References: Leendertz 2004) and chimpanzees and a gorilla in Cameroon (see References: Leendertz 2006). Investigators postulated that the chimps became ill either through consumption of an infected animal or through drinking contaminated water. Isolates from the wild apes in both outbreaks showed that the strains were clearly different from those of any previously described. The isolates established a new "forest anthrax cluster," termed F, suggesting that B anthracis is a far less homogeneous species than currently believed (see References: Leendertz 2006).

Anthrax spores were detected in two of six species of raptors (road-side hawks and chimango caracaras [a bird of prey that is in the falcon family]) in central Argentina, suggesting that scavenger and nonscavenger bird species may influence anthrax epidemiology in some countries (see References: Saggese 2007).

Anthrax has been reported in cheetahs following consumption of infected meat (see References: Good 2008).

Modes of Transmission

Illness in humans most commonly occurs following exposure to infected animals or contaminated animal products; such exposures include:

• Contact with infected tissues of dead animals (eg, butchering, preparing contaminated meat), which generally leads to cutaneous anthrax
• Consumption of contaminated undercooked meat, which can lead to gastrointestinal or oropharyngeal anthrax
• Contact with contaminated hair, wool, or hides (particularly during processing) or contact with products made from them, which can lead to either inhalational or cutaneous anthrax. Animal hair from endemic regions continues to represent an occupational risk for modern woolworkers (see References: Wattiau 2008).

Cases following laboratory exposure have been recognized (see References: Brachman 1980; CDC 2002: Suspected cutaneous anthrax in a laboratory worker). Person-to-person transmission of B anthracis has been reported rarely with cutaneous anthrax, but has not been recognized with gastrointestinal or inhalational disease (see References: Weber 2001, Weber 2002).

Anthrax in Humans—United States

• Approximately 130 cases occurred annually in the United States in the early 1900s. The incidence has gradually declined over time, with less than 10 cases reported each year since the early 1960s (see References: CDC: Summary of notifiable diseases).
• About 95% of naturally occurring cases in the United States are cutaneous and 5% are inhalational. Gastrointestinal infection has not been recognized in this country (see References: Brachman 1980).
• Only 18 cases of naturally occurring inhalational anthrax were reported in the US during the 20th century (see References: Brachman 1980). All but three were associated with industrial exposures; two of the remaining cases were laboratory-acquired and the source of exposure for the third case remains unknown.
• Between 1990 and 2000, only two cases of naturally occurring anthrax were reported in the United States (one in 1992 and one in 2000); both patients had cutaneous disease. The latter case occurred in North Dakota and resulted from agricultural exposure (see References: CDC: Human anthrax associated with an epizootic among livestock—North Dakota; CDC: Summary of notifiable diseases).
• Since 2006, three cases of anthrax have resulted from direct occupational association with djembe drums made from untreated West African animal hides. Two cases were of cutaneous anthrax (see References: CDC 2008: Cutaneous anthrax associated with drum making), and one case was inhalational (see References: CDC 2006: Inhalation anthrax associated with dried animal hides—Pennsylvania and New York City, 2006; Walsh 2007). This was the first new case of naturally occurring inhalational anthrax in the United States since 1976. In response to this case, the Centers for Disease Control and Prevention (CDC) developed a document on safety issues related to anthrax and animal hides (see References: CDC: Anthrax Q & A: anthrax and animal hides).

Anthrax in Humans—Global Perspective

• An estimated 2,000 to 20,000 human cases of anthrax occur globally each year (see References: Brachman 1984).
• Most cases are cutaneous, with inhalational and gastrointestinal cases occurring less frequently.
• Human cases generally follow disease occurrence in ruminants and are most prevalent in Africa, the Middle East, and parts of Southeast Asia.
• A recent systematic review of MEDLINE (1996-2005) and selected journal indexes (1900-1966) for inhalational anthrax cases worldwide between 1900 and 2005 identified 82 cases of inhalational anthrax (see References: Holty 2006: Systematic review: a century of inhalational anthrax cases from 1900 to 2005).
• Seventy-one of the cases were naturally occurring (11 were part of the 2001 bioterrorism outbreak in the United States, and cases from the 1979 Sverdlovsk outbreak in Russia [see section below on the epidemiology of weaponized anthrax] were excluded from analysis because symptoms, treatment, and disease progression were not described).
• Among naturally occurring cases, most involved exposure to contaminated wool, goat hair, or animal hides.

Outbreaks of Naturally Occurring Disease

Outbreaks have been reported in industrial settings where animal products are processed and in agricultural settings following consumption of or exposure to ill animals. Notable examples of outbreaks include the following:

• A major outbreak involving nearly 10,000 cases (most of them cutaneous infection) occurred in Zimbabwe during the late 1970s and early 1980s (see References: Davies 1982). An epizootic in cattle occurred at that time in the same area.
• An outbreak involving nine cases (five inhalational and four cutaneous) occurred in 1957 in the United States in a New Hampshire goat-hair processing plant (see References: Brachman 1960, Plotkin 1960). This was the last recognized outbreak of naturally occurring infection in this country.
• An outbreak of oropharyngeal anthrax involving 24 cases occurred in Thailand in 1982 following consumption of contaminated meat (see References: Sirisanthana 1984). Oropharyngeal disease is an unusual manifestation of infection, which makes this outbreak of particular interest.

Back to top

Anthrax as a Biological Weapon

Aerosol Release of Anthrax Spores

Aerosol release of weaponized spores is the most likely mechanism for use of anthrax as a biological weapon (see References: Inglesby 2002). Although there is no formal definition of weaponized anthrax, weaponization for aerosol release generally involves:

• Use of small particle size
• A high concentration of spores
• Treatment to reduce clumping
• Neutralization of the electrical charge
• Use of antimicrobial-resistant strains or genetic modification of the organism to increase virulence or escape vaccine protection

The impact of a large aerosol release of weaponized anthrax remains unknown; however, scenarios have been hypothesized, including:

• A 1970 WHO report estimated that an aerosol release of 50 kg of dried powder containing 6 x 10¹⁵ anthrax spores over a city of 5 million people in an economically developed country (such as the United States) would produce 250,000 incapacitating illnesses and up to 100,000 deaths (see References: WHO 1970).
• A 1993 Office of Technology Assessment (OTA) study estimated that up to 3 million deaths could occur following the release of 100 kg of B anthracis (see References: OTA 1993).

Recent experience with aerosol spraying of Bacillus thuringiensis in Canada to control the European gypsy moth demonstrated the following pertinent findings (see References: Levin 2003):

• Approximately 5 to 6 hours after the spray application began, indoor concentrations of airborne B thuringiensis actually exceeded outdoor concentrations, suggesting that the organisms entered homes and buildings after the aerosol release.
• Although most of the particles were relatively large, particles with a medium diameter of 2 to 7 microns were detected both inside and outside of homes. The authors estimated that, at 5 to 6 hours after spraying, adults in the spray zone inhaled approximately 203 spores per hour.
• Nasal swabs from asthmatic children in the spray zone were collected after spraying; Bacillus species with genetic patterns consistent with B thuringiensis were identified in 76.6% of isolates obtained from nasal passages.

The findings from this study suggest that it is technologically feasible to disseminate biological agents from aircraft; however, the applicability of this information to an intentional aerosol release of B anthracis is unknown. These data also raise concerns about indoor air safety should an intentional release of a biological agent occur.

Contamination of Food or Water

Deliberate contamination of food or water with anthrax spores also is a possibility. During World War II, the Japanese reportedly impregnated chocolate with anthrax to kill Chinese children. The apartheid government of South Africa also experimented with anthrax in chocolate (see References: Sirisanthana 2002).

Even though contamination of a water supply is unlikely owing to the large volume of water involved and the chlorination process, contamination of smaller water sources is theoretically feasible since spore counts remain stable in water for at least several days following inoculation (see References: Beatty 2003). Since B anthracis spores are not destroyed by pasteurization, contamination of milk is another theoretical possibility (see References: Perdue 2003).

Historical Perspective

In 1972, more than 140 countries signed the Biological and Toxin Weapons Convention, which called for termination of all offensive biological weapons research and development and destruction of existing biological weapons stocks. However, the former Soviet Union continued to expand its biological weapons program (which included weaponization of anthrax) throughout the 1980s and early 1990s.

After the demise of the Soviet Union, many of the scientists who worked in the biological weapons program left the country. The status of those scientists remains unknown; however, Iraq, Iran, Syria, Libya, and North Korea actively have recruited such experts (see References: Henderson 1999). These countries and others have been suspected of ongoing development of offensive bioweapons programs. Reports from the past few years suggest that at least five countries have offensive biological weapons programs and at least an additional five have research programs with possible production of offensive weapons (see References: Monterey Institute for International Studies).

Weaponized anthrax has caused two outbreaks of disease (key points from each are outlined in the sections below). In addition, in July 1993, the religious group Aum Shinrikyo aerosolized a liquid suspension of B anthracis from the roof of an eight-story building in the Kameido district of Tokyo, but the release did not cause any human cases. Factors contributing to failure of this bioterrorist act included use of an attenuated B anthracis strain, low spore concentration, ineffective dispersal, a clogged spray device, and inactivation of spores by sunlight (see References: Takahashi 2004).

Sverdlovsk, USSR—1979

• This outbreak in the Union of the Soviet Socialist Republics resulted from accidental release of anthrax spores from a military microbiologic facility where weaponized anthrax was being produced (see References: Meselson 1994).
• Seventy-seven human cases were reported and 66 of the patients died, for a case-fatality rate of 86%; 75 cases were inhalational and two were cutaneous (one on the back of the neck and one on the shoulder). A recent statistical analysis of available data suggests that 250 cases with 100 fatalities may actually have occurred (see References: Brookmeyer 2001).
• The mean incubation period was 9 to 10 days (range, 2 to 43 days), and the mean time between illness onset and death was 3 days.
• Mean patient age for male cases was 42 years and for female cases was 55 years, and no cases occurred in children.
• Approximately 2 weeks after the presumed date of exposure, a vaccination campaign of 59,000 eligible residents was begun; an estimated 80% of the target population received at least one dose of vaccine.
• Investigators postulated that the weight of spores released as aerosol "could have been as little as a few milligrams or as much as nearly a gram."
• Recent modeling studies suggest that the incubation period for anthrax is dose-dependent. The authors postulate that the relatively long incubation period for cases associated with Sverdlovsk was related to the level of exposure (see References: Wilkening 2006).

United States—2001

• An outbreak of cutaneous/inhalational anthrax occurred in the United States in 2001.
• The outbreak predominantly involved direct exposure to mail that was deliberately contaminated with anthrax spores. Several contaminated letters were sent and one was reported to contain 2 g of powder, with 100 billion to 1 trillion anthrax spores per gram (see References: Inglesby 2002).
• The following features were noted in an epidemiologic report that summarized the outbreak findings (see References: Jernigan 2002):
• Twenty-two cases (11 inhalational and 11 cutaneous) were identified. Five of the patients with inhalational anthrax died, for a case-fatality rate of 45% among that group.
• Cases occurred in residents of seven states along the East Coast of the United States (Connecticut, Florida, Maryland, New Jersey, New York, Pennsylvania, and Virginia), with illness onsets between September 22 and November 16, 2001.
• Four contaminated letters were recovered; all four were mailed in or around Trenton, New Jersey. Two were postmarked September 18, 2002, and two were postmarked October 9, 2002.
• Twenty of the patients were either mail handlers or were exposed to work sites where mail was handled or received; one of these cases was a 7-month-old infant. The remaining two cases had no apparent association with contaminated mail. It is likely that these persons became exposed through cross-contamination of bulk mail that passed through contaminated mail facilities (see References: Griffith 2003, Holtz 2003).
• Illness in the 7-month-old infant with cutaneous anthrax was complicated by quick progression to severe microangiopathic hemolytic anemia despite early antibiotic treatment. The source is thought to be the workplace of the infant's mother, which the infant visited the day before symptom onset. One possible exposure scenario, according to the authors, is that spores on the hands of someone in the workplace who lifted or held the child may have contacted an exposed or possibly abraded area of the child's skin (see References: Freedman 2002).
• B anthracis isolates were obtained from the four contaminated letters, 17 clinical specimens from cases, and 106 environmental samples collected along the mail path of the contaminated letters; all were identical by molecular subtyping.
• Following recognition of anthrax cases in postal workers, air sampling was conducted before and during activation of a contaminated mail-sorting machine at a Washington, DC, postal facility. This testing (which was conducted several weeks after the contaminated mail passed through the machine) demonstrated that a mail-sorting machine can remain contaminated for many days after processing mail contaminated with B anthracis (see References: Dull 2002).
• The outbreak demonstrated several important points about weaponized anthrax:
• Mail can be an effective vehicle for disseminating anthrax spores.
• Cross-contamination of mail likely can occur within postal facilities.
• Persons who handle or process unopened contaminated mail are at risk of acquiring anthrax.
• Substantial environmental contamination can occur in facilities handling contaminated mail or in offices where contaminated mail is opened.
• Following the outbreak, a case of cutaneous anthrax occurred in a laboratory worker in Texas who was working at a private laboratory that was processing environmental samples from the CDC investigations (see References: CDC: Suspected cutaneous anthrax in a laboratory worker).
• A 1-year health assessment of adult anthrax survivors demonstrated that survivors continued to report moderate to severe health complaints affecting multiple organ systems and had significantly greater overall psychological distress compared with US referent populations (see References: Reissman 2004). Fifty-three percent had not returned to work since their infection.
• The alleged perpetrator and the source of the anthrax in this outbreak have been identified. Bruce Ivins, the scientist named by Federal Bureau of Investigation (FBI) investigators as the sole orchestrator of the attack, committed suicide before he was charged. Ivins worked at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and had access to the spores used in the attack. Sequence analyses of anthrax strains allowed investigators to trace the spores to two flasks, one at USAMRIID that was under Ivin's charge and one flask from another laboratory. Several questions still remain, including the basis on which the FBI ruled out spores from the other flask and ruled out other individuals who had access to the spores. Many researchers in the scientific community remain skeptical of the FBI statements, in light of the circumstantial nature of the the evidence. The FBI is expected to close the case, in spite of the remaining unanswered questions (see References: Bhattacharjeee 2008). The original Ames strain came from a laboratory in College Station, Texas (rather than Ames, Iowa). Several distinct Ames strains have been identified.
• As a result of this outbreak, the US Postal Service has deployed an autonomous biodetection system (BDS) for anthrax in mail-processing systems across the United States (see References: CDC: Responding to detection of aerosolized Bacillus anthracis by autonomous detection systems in the workplace). See the section Use of Autonomous Detection Systems in the Workplace below for more information.

Back to top

Clinical Syndromes and Differential Diagnosis

Clinical Features of Cutaneous Anthrax
Feature	Characteristics
Incubation period	1-7 days (may be as long as 12 days)
Signs and symptomsa	—Initial lesion is small papule or vesicle, which may be pruritic. —By second day, papule ulcerates with central necrosis and drying. —Painless, localized, nonpitting edema surrounds ulcerated area. —Fine vesicles may encircle ulcer; these enlarge over next 1- 2 days and may discharge serosanguinous fluid. —After 1 to 2 days, painless black eschar forms over ulcerated area. —Eschar sloughs off after 12-14 days. —Lesions resolve without complications or scarring in 80%-90% of patients. —Extensive nonpitting edema, lymphangitis, and painful lymphadenopathy may occur. —Malignant edema is rare complication and is characterized by severe edema, multiple bullae, and shock.b —Fever and malaise are common.a —Lesions tend to occur on exposed areas of body (eg, face, hands, arms, neck). —One outbreak in Thailand demonstrated the following cutaneous findings for 13 patients with cutaneous anthraxc:    ~Eschar (85%)    ~Blister (92%)    ~Ulcer (23%)    ~Edema around lesion (77%)    ~Lymphadenopathy (100%)
Case-fatality rate	—Currently <1%a (most patients recover with appropriate antimicrobial therapy) —In preantibiotic era, case-fatality rates of about 20% were reported.d —A literature review of pediatric anthrax cases identified between 1900 and 2005 demonstrated an overall mortality rate for cutaneous disease of 14% (5 of 37 cases).e Not all cases in this report received antimicrobial therapy.
Laboratory findings	—Gram stain of lesion may reveal gram-positive rods; neutrophils are uncommon. —WBC count often is normal or may be slightly elevated.a —Histologic examination shows necrosis, edema, and lymphocytic infiltrate.f
Abbreviation: WBC, white blood cell. aSee References: Gold 1955. bSee References: Amadi 1974. cSee References: Kunanusont 1990. dSee References: Smyth 1941. eSee References: Bravata 2007. fSee References: Dixon 1999.

Clinical Features of Inhalational Anthrax
Feature	Characteristics
Incubation period	2-43 days (may be as short as 1 day or may be longer)a
Signs and symptoms	—Illness may be biphasic, with an initial prodrome (that includes symptoms such as fever, malaise, fatigue, anorexia) followed by sudden increase in fever, severe respiratory distress, diaphoresis and shock, if left untreated. —Symptoms for 10 patients with inhalational anthrax identified during the 2001 US outbreakb:    ~Fever, chills (100%) (7 were febrile on initial presentation)    ~Sweats, often drenching (70%)    ~Fatigue, malaise, lethargy (100%)    ~Cough (minimally or nonproductive) (90%)    ~Nausea or vomiting (90%)    ~Dyspnea (80%)    ~Chest discomfort or pleuritic pain (70%)    ~Myalgias (50%)    ~Headache (50%)    ~Confusion (40%)    ~Abdominal pain (30%)    ~Sore throat (20%)    ~Rhinorrhea (10%) —In the 2001 US outbreak, no evidence of a mild form of inhalational anthrax was detected through follow up serologic testing of exposed persons.b —A systematic review of 82 inhalational anthrax cases reported between 1900 and 2005 found that the most common symptoms or findings on admission included the followingc:  ~Abnormal lung findings (80%)  ~Fever or chills (67%)  ~Tachycardia (66%)  ~Fatigue or malaise (64%)  ~Cough (62%)  ~Dyspnea (52%)  ~All 26 patients who had chest radiography had abnormal findings, including pleural effusion (69%) or widened mediastinum (54%)
Case-fatality rate	—Sverdlovsk outbreak: 86%a —US outbreak: 45%d (lower observed CFR in the US outbreak likely was due to early diagnosis and aggressive therapy) —In a systematic review of 82 cases of inhalational anthrax, the overall CFR was 85%; however, patients in the US 2001 outbreak who received early antibiotic therapy (ie, during the prodromal phase [<4.7 days after illness onset]) had a CFR of 40% and those who received antibiotics >4.7 days after illness onset had a CFR of 75%c —A literature review of pediatric anthrax cases identified between 1900 and 2005 demonstrated an overall mortality rate for inhalational disease of 60% (3 of 5 cases).e Not all cases in this report received antimicrobial therapy.
Laboratory findings	Findings for 10 patients with inhalational anthrax identified during 2001 US outbreak: —Median WBC count at presentation was 9,800/mm3 (range, 7,500/mm3 to 13,300/mm3) —Differential WBC count >70% neutrophils (70%) —Band forms present (4 of 5; 40%) —Peak WBC during illness was 26,400/mm3 (range, 11,900/mm3 to 49,600/mm3) —Elevated transaminases (SGOT or SGPT) >40 (90%) —Hypoxemiaf (60%) —Metabolic acidosis (20%) —Abnormal chest radiograph (100%):    ~Mediastinal widening (70%)    ~Infiltrates, consolidation (70%)    ~Pleural effusion (80%) —Abnormal CT scan (8 of 8; 100%):    ~Mediastinal lymphadenopathy, widening (7 of 8; 88%)    ~Pleural effusion (8 of 8; 100%)    ~Infiltrates, consolidation (6 of 8; 75%)
Abbreviations: CFR, case-fatality rate; CT, chest-computed tomography; SGOT, serum glutamic oxalacetic transaminase; SGPT, serum glutamic pyruvic transaminase; WBC, white blood cell. aSee References: Meselson 1994. bSee References: Baggett 2005. cSee References: Holty 2006. dSee References: Jernigan 2001. eSee References: Bravata 2007. fAlveolar-arterial oxygen gradient >30 Hg on room air; O2 saturation <94%.

Clinical Features of Gastrointestinal and Oropharyngeal Anthrax
Feature	Characteristics
Incubation period	1-7 days (usually 2-5 days)
Signs and symptoms	—One outbreak in Uganda demonstrated the following findings in 143 patientsa:    ~Fever (may be low-grade) (70%)    ~Abdominal tenderness (85%)    ~Diarrhea (80%; bloody in only 5%)    ~Vomiting (may be coffee-ground or blood-tinged) (90%)    ~Headache (100%)    ~Pharyngeal edema (10%) —Ascites may develop 2-4 days after onset (fluid may be clear or purulent)b —Ulcerations can occur anywhere along the GI tract and may cause hemorrhage, obstruction, or perforationc —If the patient survives, symptoms last about 2 wk —One outbreak of oropharyngeal anthrax in Thailand demonstrated the following findings for 24 patientsd:    ~Neck swelling (100%)    ~Fever (96%)    ~Sore throat, dysphagia (63%)    ~Mouth or pharyngeal ulcerative or necrotic lesions (100%) (pseudomembranes also were noted in some patients)    ~Respiratory distress (25%)    ~Hoarseness (8%)    ~Sensation of a "lump in throat" (8%)    ~Diarrhea (4%)    ~Bleeding from the mouth (4%)
Case-fatality rate	—Rate for GI anthrax is between 25% and 60%.e In outbreaks where patients received antibiotic therapy, rates have ranged from 0% to 29%.f —A literature review of pediatric anthrax cases identified between 1900 and 2005 demonstrated an overall mortality rate for gastrointestinal disease of 65% (13 of 20 cases).g Not all cases in this report received antimicrobial therapy. —In Thailand outbreak of oropharyngeal disease, rate was 13%.d In another report of 6 cases of pharyngeal anthrax, rate was 50%.h
Laboratory findings	—Gram stain of peritoneal fluid or oropharyngeal ulcers may demonstrate gram-positive rods. —Median WBC count for 13 patients with oropharyngeal anthrax in Thailand outbreak was 15,635/mm3 (range, 5,100/mm3 to 30,570/mm3). Mean percentage of neutrophils was 79.6% (range, 73% to 91%). —B anthracis has been cultured from oropharyngeal swaps and stool specimens in patients with GI anthrax.f
Abbreviations: GI, gastrointestinal; WBC, white blood cell. aSee References: Ndyabahinduka 1984. bSee References: Dixon 1999. cSee References: Sirisanthana 2002. dSee References: Sirisanthana 1984. eSee References: CDC: Investigation of anthrax associated with intentional exposure and interim public health guidelines. fSee References: Beatty 2003. gSee References: Bravata 2007. hSee References: Doganay 1986.

Clinical Features of Anthrax Meningitis
Feature	Characteristics
Incubation period	Varies according to primary source of infection.
Signs and symptomsaa-d§	—May occur as complication of cutaneous, inhalational, or gastrointestinal anthrax and symptoms of primary site of infection usually will be present; however, meningitis may be the presenting illness. —Characteristic features of bacterial meningitis usually present (eg, fever, nuchal rigidity, headache, change in mental status, seizures). —Nausea and/or vomiting are common. —Hemorrhagic meningoencephalitis is a characteristic presentation.
Case-fatality ratee	—Illness fatal in >90% of cases. —A literature review of pediatric anthrax cases identified between 1900 and 2005 demonstrated an overall mortality rate for meningoencephalitis of 100% (6 of 6 cases).f Not all cases in this report received antimicrobial therapy. —Death usually occurs 1 to 6 days after illness onset, and 75% of patients die within 24 hr of presentation.
Laboratory findings	—Gram stain of CSF reveals many gram-positive rods. —CSF is usually bloody. —Report of two cases demonstrated elevated WBC counts in both patients at presentation (24,000 with 84% neutrophils and 18,000 with 90% neutrophils).b —CT or MRI of head may show focal intracerebral hemorrhage, subarachnoid hemorrhage, diffuse cerebral edema, intraventricular hemorrhage, and/or leptomeningeal enhancement.d
Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; MRI, magnetic resonance imaging; WBC, white blood cell. aSee References: Dixon 1999. bSee References: Rangel 1975. cSee References: Meyer 2003. dSee References: Sejvar 2005 eSee References: Lanska 2002 fSee References: Bravata 2007.

Differential Diagnosis

The differential diagnosis for anthrax depends upon the clinical syndrome (inhalational, cutaneous, gastrointestinal, or meningeal). Other diagnoses to consider are outlined in the tables below.

Differential Diagnosis for Cutaneous Anthrax
(Note: Two key features that distinguish cutaneous anthrax from other conditions in differential diagnosis are painlessness of the lesion and the relatively large extent of associated edema.)
Diagnosisa-c	Distinguishing Features
Ecthyma gangrenosum	—Usually in neutropenic patients with Pseudomonas aeruginosa bacteremia —Edema usually not present
Ulceroglandular tularemia (Francisella tularensis)	—Clinical course usually indolent; disease often self-limited —Systemic toxicity uncommon
Bubonic plague (Yersinia pestis)	—Systemic toxicity common —Extremely tender regional lymphadenopathy present —Ulceration and eschar formation usually absent
Staphylococcal or streptococcal cellulitis	—May be history of trauma or preexisting lesion at site of infection —Eschar formation does not occur —Usually painful
Necrotizing soft tissue infections (particularly Group A streptococcus and Clostridium species)	—Severe systemic toxicity often present —Early in course, pain usually more severe than clinical findings would indicate
Bite of brown recluse spider (Loxosceles reclusa)d	—Brown recluse spiders prefer warm temperatures and are not native to Northern half of United States —Spiders tend to hide in barns, woodpiles, and similar places —Bite usually causes painful blister which progresses to necrosis (unlike anthrax, which is painless) —Edema generally absent
Rickettsialpox (Rickettsia akari)	—Initial presentation involves painless papule which forms black eschar —Generalized maculopapular rash appears 2-3 days later
Scrub typhus (Orientia tsutsugamushi; formerly Rickettsia tsutsugamushi)	—Zoonotic infection from chigger bites; occurs in endemic areas (Asia and Western Pacific) —Often associated with generalized maculopapular rash
Orf (orf virus, a parapox virus)	—Occurs in farm workers —Characterized by pustule that progresses to weeping nodule —Eschar formation does not occur —Edema usually absent
Necrotic herpes simplex infection	—More likely to occur in immunocompromised host
aSee References: Dixon 1999. bSee References: Swartz 2001. cSee References: Bell 2002. dSee References: Nelson 2002.

Back to top

Differential Diagnosis for Inhalational Anthrax
(Note: Features that distinguish inhalational anthrax from other conditions in differential diagnosis include presence of widened mediastinum and pleural effusions on chest radiograph or CT scan with minimal evidence of pneumonia)
Diagnosisa,b	Distinguishing Features
Pneumonic plague (Yersinia pestis)	—Hemoptysis relatively common with pneumonic plague, but rare with inhalational anthrax
Tularemia (Francisella tularensis)	—Clinical course usually indolent, lasting weeks —Less likely to be fulminant
Community-acquired bacterial pneumonia —Mycoplasmal pneumonia (Mycoplasma pneumoniae) —Pneumonia caused by Chlamydia pneumoniae —Legionnaires' disease (Legionella pneumophila or other Legionella species) —Psittacosis (Chlamydia psittaci) —Other bacterial agents (eg, Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis)	—Rarely as fulminant as inhalational anthrax —Legionellosis and many other bacterial agents (S aureus, S pneumoniae, H influenzae, K pneumoniae, M catarrhalis) usually occur in persons with underlying pulmonary or other disease or in elderly —Bird exposure with psittacosis —Gram stain of sputum may be useful —Community outbreaks caused by other etiologic agents not likely to be as explosive as pneumonic plague outbreak —Outbreaks of S pneumoniae usually institutional —Community outbreaks of Legionnaires' disease often involve exposure to cooling towers
Viral pneumonia —Influenza —Hantavirus —RSV —CMV	—Influenza generally seasonal (October-March in United States) or involves history of recent cruise ship travel or travel to tropics —Exposure to mice droppings, feces with Hantavirus —RSV usually occurs in children (although may be cause of pneumonia in elderly); tends to be seasonal (winter/spring) —CMV usually occurs in immunocompromised patients
—Q fever (Coxiella burnetii)	—Exposure to infected parturient cats, cattle, sheep, goats —Severe pneumonia not prominent feature
Abbreviations: CMV, cytomegalovirus; CT, computed tomography; RSV, respiratory syncytial virus. aSee References: Dixon 1999. bSee References: Bell: Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax.

Back to top

Differential Diagnosis for Gastrointestinal and Oropharyngeal Anthrax
Diagnosis	Distinguishing Features
Gastrointestinal Anthraxa
Typhoid fever (Salmonella typhi)	—Ascites usually not present —Other clinical features may be similar
Intestinal tularemia (Francisella tularensis)	—Illness often less severe than that seen with gastrointestinal anthrax —Ascites not present —Less likely to resemble acute abdomen —Fever may be less prominent
Bacillary dysentery (Shigella dysenteriae)	—Ascites usually not present —Other clinical features may be similar
Acute bacterial gastroenteritis caused by other agents (eg, Campylobacter jejuni, Shiga toxin–producing Escherichia coli, Yersinia enterocolitica)	—Illness often less severe than that seen with gastrointestinal anthrax —Ascites not present —Less likely to resemble acute abdomen —Fever may be less prominent —Hemolytic uremic syndrome may occur with infection caused by Shiga toxin–producing E coli
Bacterial peritonitis	—Gastrointestinal symptoms (nausea, vomiting, gastrointestinal bleeding, diarrhea) not prominent features —Tends to occur in persons with underlying medical conditions (eg, alcoholism, other liver disease)
Acute abdomen (eg, appendicitis)b	—Anthrax generally begins with vague systemic symptoms rather than abdominal pain —Ascites is relatively common with gastrointestinal anthrax and less common with appendicitis and similar conditions
Oropharyngeal Anthrax
Diphtheria (Corynebacterium diphtheriae)	—Primarily occurs in nonimmune children under 15 yr of age —Pharyngeal membrane is prominent feature; ulcerative or necrotic lesions generally not present —Removal of pharyngeal membrane often causes bleeding of submucosa
Pharyngeal tularemia (Francisella tularensis)	—Neck swelling usually absent —Exudative pharyngitis common; ulcerative lesions may occur
Streptococcal pharyngitis (Streptococcus pyogenes)	—Exudative pharyngitis most prominent feature; necrotic ulcers generally absent —Neck edema usually absent, although cervical lymphadenopathy may be prominent
Infectious mononucleosis	—Most common in young adults —Splenomegaly commonly occurs —Neck edema usually absent, although cervical lymphadenopathy may be prominent
Enteroviral vesicular pharyngitis (coxsackievirus)	—Small vesicles noted on soft palate, uvula, or anterior tonsillar pillars —Generally occurs in children —Neck edema usually absent
Acute herpetic pharyngitis (herpes simplex virus)	—Vesicles, shallow ulcers may be noted, but lesions usually not necrotic —Neck edema usually absent, although cervical lymphadenopathy may be prominent
Anaerobic pharyngitis (Vincent's angina)	—Purulent exudate covers posterior pharynx —Tonsillar abscesses may occur —Neck edema usually absent
Yersinia enterocolitica pharyngitis	—Exudative pharyngitis most prominent feature —Neck edema usually absent —Cervical adenopathy, abdominal pain may occur
aSee References: Dixon 1999. bSee References: Kanafani 2003.

Back to top

Differential Diagnosis for Anthrax Meningitis
Diagnosis	Distinguishing Features
Subarachnoid hemorrhage	—Fever not usually prominent feature —Can be distinguished by computed tomography without contrasta
Bacterial meningitis from other causes	—Meningitis not usually hemorrhagic as seen with anthrax meningitis —CSF gram stain may be useful in diagnosis
Aseptic meningitis	—Meningitis not hemorrhagic —CSF does not show characteristic gram-positive bacilli —CSF usually demonstrates lymphocytosis
Encephalitis	—CSF findings may be variable, depending on etiology —CSF Gram stain may be useful in diagnosis
Abbreviations: CSF, cerebrospinal fluid. aSee References: Dixon 1999.

Back to top

Staging of Inhalational Anthrax

Historically, inhalational anthrax has been divided into a prodromal phase and a fulminant phase. The table below outlines a proposed staging scheme (see References: Lucey 2005) that adds an intermediate stage in which symptoms are clearly worsening but the illness may still be treated successfully.

Proposed Staging of Inhalational Anthrax
Stage	Comments
1: Asymptomatic	—Usually <1 wk after exposure and rarely >1 mo
2: Early—Prodromal	—Nonspecific malaise, myalgias, low-grade fever, mild headache, nausea, general “flu-like” prodromal illness
3: Intermediate—Progressive	—Blood cultures positive in <24 hr —Mediastinal lymphadenopathy —Pleural effusions that are often hemorrhagic, large, and require repeated drainage —Findings may include: high fever, dyspnea, confusion or syncope, increasing nausea/vomiting —Patients at this stage can still be cured with antibiotics and intensive support
4: Late—Fulminant	—Respiratory failure requiring intubation, meningitis, end-organ hypoperfusion (ie, “shock”) —Cure less likely at this stage —Future therapies for this stage may require inhibitors of both anthrax toxin and systemic inflammatory response, in addition to antibiotics and intensive care
Adapted from Lucy 2005 (see References).

Distinguishing Inhalational Anthrax from Influenza-Like Illness (ILI) and Community-Acquired Pneumonia (CAP)

Early symptoms of inhalational anthrax, ILI, and CAP are similar and include fever, chills, myalgias, fatigue, malaise, and cough. However, several features can be used to distinguish these illnesses. One study of symptomatic patients with possible exposure to anthrax found that the presence of nonheadache neurologic symptoms (eg, dizziness, confusion); dyspnea; and upper gastrointestinal tract symptoms (eg, nausea, vomiting) were more suggestive of anthrax, whereas rhinorrhea and sore throat were far more common in patients with viral illnesses (see References: Hupert 2003).

Another study reviewed the CDC guidelines for inhalational anthrax during the 2001 outbreak and found that the guidelines would have missed 10 of the 11 cases (see References: Mayer 2003). The authors found that the modifications to the CDC guidelines shown below in italics would have led to recognition of eight of the 11 cases.

• Fever
• Sweats
• Fatigue
• Cough
• Chest discomfort, pleuritic pain
• Nausea/vomiting
• Headache
• Dyspnea
• Myalgias
• Abdominal pain
• Confusion
• Fever (low grade: mean, T 38°C)
• Tachycardia (mean heart rate, 121 beats per minute)
• Clinical presentation consistent with inhalational anthrax when five or more of the above symptoms are present, in addition to tachycardia and fever

Howell and colleagues have suggested that use of this screening protocol may incur lower medical costs than the screening protocol proposed by Hupert and coworkers (outlined in the first paragragh of this section) and may be similar in its sensitivity to detect anthrax cases (although the numbers of anthrax cases in the comparison study were small) (see References: Howell 2004, Hupert 2003).

Another study examined the clinical features of the 2001 inhalational anthrax cases and compared them with those of ILI cases seen in an ambulatory clinic and of hospitalized patients with CAP. On the basis of these comparisons, the authors developed scoring systems for distinguishing ILI and CAP from inhalational anthrax (see References: Kuehnert 2003).

• The scoring system for comparing inhalational anthrax with ILI included the following features. Patients with a score of 4 or more were more likely to have inhalational anthrax (sensitivity, 100%; specificity, 96.1%) than those with lower scores.
• Low serum albumin (2 points)
• Tachycardia (2 points)
• No nasal symptoms (2 points)
• No myalgias or arthralgias (1 point)
• Low serum sodium level (1 point)
• No headache (1 point)
• High hematocrit or hemoglobin level (1 point)
• The scoring system for comparing inhalational anthrax with CAP included the following features. Patients with a score of 2 or more were more likely to have inhalational anthrax (sensitivity, 100%; specificity, 48%) than those with lower scores. When the score was increased to 3 or more, the sensitivity dropped to 82% and the specificity increased to 81%.
• Elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels (1 point)
• Low serum sodium level (1 point)
• Normal white blood cell count (1 point)
• Nausea and vomiting (1 point)
• Tachycardia (1 point)

A third study, which compared 47 historical anthrax cases (including 11 with bioterrorism-related anthrax) with 376 controls with CAP or ILI, found that the most accurate predictor of anthrax was mediastinal widening or pleural effusion on chest radiograph (see References: Kyriacou 2004).

A report from the CDC included the following table, which compared the clinical features of 10 patients with inhalational anthrax to patients with laboratory-confirmed influenza.

Symptoms and Signs of Inhalational Anthrax, Laboratory-Confirmed Influenza, and Influenza-Like Illness (ILI) from Other Causes
	Inhalational Anthrax* (%)	Laboratory-Confirmed Influenza (%)	ILI from Other Causes (%)
Elevated temperature	70	68-77	40-73
Fever or chills	100	83-90	75-89
Fatigue/malaise	100	75-94	62-94
Cough	90	84-93	72-80
Shortness of breath	80	6	6
Chest discomfort/pain	60	35	23
Headache	50	84-91	74-89
Myalgias	50	67-94	73-94
Sore throat	20	64-84	64-84
Rhinorrhea	10	79	68
Nausea or vomiting	80	12	12
Abdominal pain	30	22	22
*N=10. Adapted from CDC. Considerations for distinguishing influenza-like illness from inhalational anthrax (see References).

A literature review of 42 patients who had atypical anthrax presentations (ie, patients with confirmed anthrax infection who did not have known cutaneous, gastrointestinal, or inhalational ports of entry) revealed that these patients were significantly less likely to have cough, chest pain, or abnormal lung findings, even though they most likely had inhalational anthrax (see References: Holty 2006: Anthrax: a systematic review of atypical presentations).

A 2004 study used a decision-analytic model to assess the best treatment strategy for patients presenting with influenza-like illness in settings with varying probabilities for inhalational anthrax (see References: Fine 2004). The authors concluded that for inhalational anthrax probabilities between 0.1% and 2%, when the sensitivity of blood culture exceeds 95%, the best strategy is to treat with a short course of empiric ciprofloxacin until blood culture results are available. During influenza season, the best strategy involves rapid testing for influenza followed by empiric treatment for anthrax pending blood culture results for those who test negative for influenza.

Pediatric Considerations

Reports in the literature support the following observations about anthrax in children.

• Inhalational anthrax is uncommon in children. For example, none of the cases in the Sverdlovsk inhalational anthrax outbreak occurred in children (see References: Meselson 1979) and reports of inhalational disease among children are rare.
• Naturally occurring cutaneous anthrax also is uncommon in children, probably because children have less opportunity for exposure to infected animals.
• Other modes of transmission (such as person-to-person through skin-to-skin contact or transmission via fomites) may be more common for young children who acquire cutaneous anthrax (see References: Freedman 2002).
• The skin lesions described for children who have cutaneous anthrax are usually similar to those seen in adults. Progression to severe systemic disease can occur (see References: Freedman 2002).
• Anthrax meningitis has been reported in children and may be the presenting feature (see References: Rangel 1975, Tabatabaie 1979).
• A review of 73 cases (5 inhalational, 22 gastrointestinal, 37 cutaneous, 6 primary meningoencephalitis, and 3 atypical) in children from 1900 to 2005 noted that children with inhalational anthrax lacked nonheadache neurologic symptoms, a key distinguishing finding (see References: Bravata 2007).
• Another review of 62 pediatric cases of anthrax (2 inhalational, 20 gastrointestinal, 37 cutaneous, and 3 atypical) between 1966 and 2005 suggests that infected children may manifest different symptoms than do infected adults and that difficulties in diagnosing the disease in children may lead to delays in care (see References: AHRQ 2006: Pediatric anthrax). Children with gastrointestinal anthrax have two distinct clinical presentations similar to adults; however, children with inhalational anthrax may have atypical presentations including meningoencephalitis. Clinicians and public health officials must recognize the broad spectrum of potential presentations for timely diagnosis and detection.

Anthrax During Pregnancy

A recent report summarized two cases of anthrax in pregnant women; the features of these cases are outlined in the table below (see References: Kadanali 2003).

Summary of Clinical Features for Two Pregnant Women with Anthrax
Patient Age	Weeks of Gestation at Illness Onset	Clinical Presentation of Anthrax	Outcome of Pregnancy
33	32	Cutaneous anthrax (treated with penicillin G and prednisone)	—Infant delivered preterm at 35 wk —No evidence of congenital infection
29	33	Cutaneous anthrax (treated with procaine penicillin)	—Infant delivered preterm at 34 wk —No evidence of congenital infection

Back to top

Clinical Laboratory Testing

Specimen Collection and Transport

When the diagnosis of anthrax is being considered, the hospital clinical laboratory should be alerted because some laboratories will not further identify Bacillus species unless specifically requested. The following table outlines the collection of laboratory specimens for diagnosis of anthrax.

Collection and Transport of Laboratory Specimens for the Diagnosis of Anthraxa-d
Type of illness	Specimen collectione and transport	Commentsf,g
Cutaneous anthraxh	—All stages: Collect 2 swabs, one for Gram stain and culture, and 1 for PCR. —Vesicular stage: Perform Gram stain, culture, and PCR of fluids from unroofed vesicle (soak two dry sterile swabs in vesicular fluid). Note: Gram stain is most sensitive during vesicular stage. —Eschar stage: Perform Gram stain, culture, and PCR of ulcer base or edge of eschar without removing it. —Ulcer (no vesicle or eschar present): swab base of ulcer with pre-moistened sterile saline —A punch biopsy for IHC testing and a second biopsy for culture, Gram stain, PCR, and frozen-tissue IHC if patient has not received antibiotics should be obtained on all patients with suspected cutaneous anthrax. Include skin adjacent to papule or vesicle. If vesicles and eschars are both present, separate biopsies should be obtained. —Serum: collect acute serum within first 7 days of symptom onset, and convalescent serum 14-35 days after symptom onset. —Collect blood for culture and PCR with evidence of systemic involvement.	—Swabs: moisten with sterile saline or water; transport in sterile tube at at 2o-8oC Transport swabs for PCR only at –70oC. Do not use transport medium. —Tissue, fresh: >5 mm3; store and transport at 2o-8oC (<2 hr) or frozen at –70oC (>2 hr). —Tissue, preserved in 10% buffered formalin: 1.0 cm3; store and transport at room temperature. —Biopsy of lesions for histopathology, preserved in 10% buffered formalin: 0.3 mm diameter, store and transport at room temperature. —Freeze serum after separation at –20oC or colder, ship on dry ice. Ship part of sample (>1.0 mL) and retain part in case of shipping problems.i —Obtain blood for culture per local protocol. Collect blood for PCR in EDTA (purple top) tube. Ship at room temperature (<2 hr transport) or 2-8oC (>2 hr transport).
Inhalational anthraxi	—If sputum is being produced, collect sputum specimen for Gram stain and culture (note: inhalational anthrax does not usually result in sputum production). —Obtain blood for smear, culture, and PCR). —If a pleural effusion is present, collect a specimen for culture, Gram stain, and PCR —Collect CSF if meningeal signs are present or meningitis is suspected for culture, Gram stain, and PCR. —Serum: collect acute serum within 1st 7 days of symptom onset, and convalescent serum 14-35 days after symptom onset. —Biopsy material: bronchial or pleural biopsy material can be evaluated if available.	—Sputum: transport at room temperature in sterile, screw-capped container (<1 hr transport time) or at 2o-8oC (>1 hr transport time). —Blood cultures: Obtain appropriate blood volume, number, and timing of sets per laboratory protocol; transport at room temperature. —Blood for PCR: 10 mL in EDTA (for pediatric patients collect volumes allowable). Transport directly to laboratory at room temperature (2-8oC if transport > 2 hr). —Pleural fluid: Collect > 1 mL in sterile container. Store and transport at 2-8oC. —CSF: Transport directly to laboratory at room temperature, or 2-8oC if transport >2 hr. —Transport serum or citrated plasma (separated and removed from clot) at 2-8oC (transport <2 hr) or freeze at –20oC or colder (transport >2 hr), ship on dry ice. Ship part of sample (>1.0 mL) and retain part in case of shipping problems.j —Preserve biopsies in 10% buffered formalin, and transport at room temperature.
Gastrointestinal anthrax	—Obtain stool specimen for culture (>5 g). —Obtain rectal swab from patients unable to produce stool (insert swab 1 in. beyond anal sphincter). —Obtain blood for smear and culture (and possibly PCR testing). —Blood cultures most likely to yield B anthracis if taken 2-8 days postexposure and prior to administration of antibiotics. —If ascites is present, obtain a specimen for Gram stain and culture (and possibly PCR testing).	—Stool: Transport in sterile container unpreserved (<1 hr transport time) or at 2o-8oC in Cary-Blair medium or equivalent (>1 hr transport time); specimen >5.0 g. —Blood: Transport at room temperature.
Anthrax meningitis	—Obtain CSF specimen for Gram stain, culture, and PCR. —Obtain blood for Gram stain, culture, and PCR.	—See comments above for collection and transport of blood and CSF for Gram stain, culture, and PCR.
Abbreviations: CSF, cerebrospinal fluid; EDTA, ethylenediaminetetraacetic acid; IHC, immunohistochemistry; PCR, polymerase chain reaction. aSee References: CDC/ASM/APHL 2002. bSee References: CDC: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. cSee References: Bell 2002. dSee References: CDC. Algorithm for laboratory diagnosis of anthrax. eSerologic testing may be useful in certain situations for retrospective diagnosis, since antibodies take several weeks to develop. Serum should be collected during the acute illness, and 14, 28, 42, and 60 days after onset (see References: CDC: Clinical diagnosis and management of anthrax—lessons learned). fConsult with testing laboratory for specific instructions. gSee References: CDC: Acceptable biological specimens needed for testing for anthrax. hSee References: CDC. Cutaneous anthrax: recommended specimens for microbiology and pathology for diagnosis. iSee References: CDC. Inhalation anthrax: recommended specimens for microbiology and pathology for diagnosis. jSee References: CDC. Anthrax: collecting, preparing, and shipping serum samples to CDC for serology testing.

Guidelines have been published for packing and shipping of infectious substances, diagnostic specimens, and biological agents from suspected bioterrorism (see References: ASM). Chain-of-custody should be documented for material that may constitute evidence of criminal activity.

B anthracis is classified under World Health Organization (WHO) risk group 4. Isolates that are reasonably suspected to contain B anthracis must be transported as "infectious substances." International Air Transport Association (IATA) rules require training of all individuals involved in the transport of dangerous goods, including infectious substances. Once B anthracis is identified, isolates and specimens are regulated as select agents and are subject to additional transport requirements (see below).

Laboratory Biosafety and Biosecurity Information

• Most clinical and environmental screening can be conducted under biosafety level 2 (BSL-2) conditions. The B anthracis cells present in clinical samples are primarily vegetative, which are not easily transmitted to laboratory workers. However, most hospital laboratories are not sufficiently staffed, trained, or equipped for environmental testing. The recent case of cutaneous anthrax in a laboratory worker illustrates this potential risk (see References: CDC: Case of cutaneous anthrax in a laboratory worker).
• Anthrax spores may remain viable after standard DNA purification procedures (see References: Rantakokko-Jalava 2003). Experimental heat treatment of anthrax spores at 121^oC for 45 minutes appears to eliminate viability without significantly affecting polymerase chain reaction (PCR) efficiency (see References: Fasanella 2003). Spores can also be irradiated with gamma rays to inactivate them without affecting PCR results (see References: Dauphin 2008).
• Inadvertent exposure to B anthracis spores occurred in 2004 in a California laboratory when workers used a suspension from a contract laboratory that was supposed to contain nonviable vegetative cells but actually contained viable B anthracis spores (see References: CDC: Inadvertent laboratory exposure to Bacillus anthracis—California 2004). Following this report, the CDC stated that "Research laboratory workers should assume that all inactivated B anthracis suspension materials are infectious until inactivation is adequately confirmed."
• Biosafety level 3 (BSL-3) practice are required for "production quantities or concentrations of cultures, or activities with a high potential for aerosols" including suspect powders.
• BSL-2 and BSL-3 criteria and practices are described elsewhere (see References: CDC: Biosafety in microbiological and biomedical laboratories).
• B anthracis is classified as a select agent and therefore is regulated under 42 CFR part 73 (Possession, Use, and Transfer of Select Agents and Toxins), which was published in final form in the Federal Register in March 2005 (see References: HHS). As specified in the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, 42 CFR part 73 provides requirements for laboratories that handle select agents (including registration, security risk assessments, safety plans, security plans, emergency response plans, training, transfers, record keeping, inspections, and notifications). For more information about the CDC's Select Agent Program, see References: CDC: Select Agent Program. In addition, the CDC has published additional guidelines for enhancing laboratory security for laboratories working with select agents (see References: CDC: Laboratory security and emergency response guidance for laboratories working with select agents).

The Laboratory Response Network (LRN)

The Laboratory Response Network (LRN) is a national network of approximately 150 laboratories. The network includes the following types of labs: federal, state and local public health, military, food testing, environmental, veterinary, and international (located in Canada, the United Kingdom, and Australia) (see References: CDC: Facts about the Laboratory Response Network).

The LRN structure for bioterrorism designates laboratories as either national, reference, or sentinel. Designation depends on the types of tests a laboratory can perform and how it handles infectious agents to protect workers and the public.

• National laboratories have unique resources to handle highly infectious agents and the ability to identify specific agent strains.
• Reference laboratories, sometimes referred to as “confirmatory reference,” can perform tests to detect and confirm the presence of a threat agent. These laboratories ensure a timely local response in the event of a terrorist incident. Rather than having to rely on confirmation from laboratories at the CDC, reference laboratories are capable of producing conclusive results; this allows local authorities to respond quickly to emergencies. These are mostly state or local public health laboratories with BSL-3 containment facilities that have been given access to nonpublic testing protocols and reagents.
• Sentinel laboratories represent the thousands of hospital-based labs that are on the front lines. Sentinel laboratories have direct contact with patients. In an unannounced or covert terrorist attack, patients provide specimens during routine patient care. Sentinel laboratories could be the first facility to spot a suspicious specimen. A sentinel laboratory’s responsibility is to refer a suspicious sample to the right reference laboratory. These laboratories generally have at least BSL-2 containment.

Standard Tests for Detection of B anthracis

Direct examination of bacterial micromorphology may demonstrate broad encapsulated gram-positive rods (approved for LRN sentinel [formerly level A] laboratories).

• Gram stain can be performed on appropriate clinical specimens (eg, vesicular fluid, swabs from cutaneous lesions, cerebrospinal fluid [CSF], pleural fluid) (see References: Bell: Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax; Inglesby 2002). Two positive Gram stain findings, one from CSF and one buffy-coat smear, recently were reported in cases of inhalational anthrax (see References: Jernigan 2001).
• The sensitivity of the Gram stain and other biologic stains (eg, H&E, silver stain) for direct detection of anthrax cells in infected tissues or blood has not been established. However, the organism appears to be present in large numbers in advanced cases, which suggests the probable utility of direct smears in those presenting with advanced disease (see References: CDC: Clinical diagnosis and management of anthrax—lessons learned; Inglesby 2002). In cutaneous anthrax, B anthracis cells are most likely to be seen by Gram stain during the vesicular stage of disease (see References: CDC/ASM/APHL 2002).
• Buffy-coat smears may be positive in patients with bacteremia. The specific usefulness of buffy coat for early diagnosis of bacteremia has been out of favor owing to early reports of low predictive value, but its use for anthrax has not been adequately studied (see References: Coppen 1981). PCR of buffy-coats has been successfully used for diagnosis of other bloodstream infections both before and after antibiotic treatment (see References: Michelow 2002, Newcombe 1996). The PCR detection limit in simulated blood specimens was 400 colony-forming units (CFU)/mL (see References: Rantakokko-Jalava 2003).
• Endospores and free spores can be seen in cultures and generally are not seen in direct microscopic examination of patient samples (see References: CDC: Clinical diagnosis and management of anthrax—lessons learned).
• India ink staining (sentinel laboratories) or M'Fadyean stain (reference laboratories) can be performed for capsule visualization directly on clinical specimens (see References: CDC: Approved tests for the detection of Bacillus anthracis in the Laboratory Response Network).

Culture of clinical specimens is the "gold standard" for diagnosis of anthrax (initial isolation approved for LRN sentinel laboratories) (see References: CDC/ASM/APHL 2002; CDC: Approved tests for the detection of Bacillus anthracis in the Laboratory Response Network).

• Culture should be performed using standard 5% sheep blood agar. After 15 to 24 hours of incubation at 35°C to 37°C, colonies are 2 to 5 mm in diameter, flat or slightly convex, irregularly round, and slightly irregular or have a wavy border and a ground-glass appearance. Colonies typically have a tenacious consistency (ie, teasing with an inoculating loop causes the colony to stand up like beaten egg white).
• Motility is measured by wet mount (working in a BSL-2 cabinet) or by motility test medium.
• Spores are visualized by Gram stain (sentinel laboratories), wet mount, or malachite green (reference laboratories) from cultures incubated for 18 to 24 hours at 35°C to 37°C without enhanced CO₂. Spores are oval, are central to subterminal, and do not appreciably swell the mother cell.
• India ink for demonstration of capsule can be used on cultures grown on media supplemented with sodium bicarbonate.
• Suspicious isolates should be forwarded to an LRN reference laboratory for confirmatory identification.
• Blood culture sensitivity is compromised when samples are collected after administration of even one or two doses of antibiotics; therefore, cultures should be obtained before antibiotic therapy is initiated. If antibiotics have been administered, alternate diagnostic methods should be considered.

Stepwise Identification and Confirmation

Presumptive identification of anthrax in clinical specimens is based on Gram stain morphology and detection of a capsule (see References: CDC/ASM/APHL 2002). NOTE: The absence of evidence for a capsule does not rule out B anthracis.

• Large gram-positive rods in short chains of 2 to 4 cells: Possible Bacillus species
• India ink test positive (evidence of encapsulation): Presumptive B anthracis
• Other tests conducted at LRN laboratories may provide additional direct evidence of anthrax; definitive identification is by culture

Standard identification of isolates is based on classical biochemical and morphologic characteristics (see References: Sneath 1986; CDC/ASM/APHL 2002). A stepwise protocol for identification of B anthracis is as follows:

• Gram-positive broad spore-forming rods: Bacillus species
• Spores are nonswelling and oval-shaped, and colonies have a ground-glass appearance: Bacillus morphology group 1 (includes B anthracis, B cereus, B thuringiensis, and B cereus var mycoides)
• Nonmotile: B anthracis and B cereus var mycoides
• Nonhemolytic: presumptive B anthracis (weak hemolysis may be observed under areas of confluent growth in aging colonies and should not be confused with beta-hemolysis)

Standard confirmatory testing (performed by LRN reference and national laboratories) includes the following tests (see References: CDC: Approved tests for the detection of Bacillus anthracis in the LRN; CDC: Algorithm for laboratory diagnosis of anthrax):

• Lysis by gamma phage (provides confirmatory testing when demonstrated concomitantly with the presence of a capsule). Performance characteristics have been described in detail (see References: Abshire 2005).
• Direct immunofluorescent assays (DFA) for cell-wall-associated polysaccharide and capsule produced by vegetative cells (demonstration of both antigens provides confirmatory identification) (see References: De 2002).
• Additional test procedures for visualizing spores by LRN reference laboratories include wet mount and malachite green stain.
• PCR-based assays for rapid identification of B anthracis:
• A real-time PCR assay for rapid identification of B anthracis was evaluated by the CDC during the 2001 anthrax outbreak (see References: Hoffmaster 2002: Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis). Sensitivity and specificity were reported as 100%. PCR testing for anthrax is available through the LRN.
• Real-time PCR assays capable of detecing multiple agents have been developed and are able to detect B anthracis, Francisella tularensis, and Yersinia pestis in a single assay without any cross-reactivity. The assay may prove useful as a rapid tool for detection of Category A bioterrorism agents (see References: Skottman 2007). Commercial ready-to-use reagent systems have been developed for use in PCR assays (see References: Sohni 2008).
• PCR primers that distinguish B anthracis from related Bacillus species have been developed. The primers may be useful for developing an efficient diagnostic tool for rapid identification (see References: Kim 2008). A restriction site insertion–PCR (RSI-PCR) method can distinguish B cereus group strains closely related to B anthracis from B anthracis strains (see References: Gierczynski 2007).
• Immunohistochemistry (IHC) is a sensitive and specific method for detection of B anthracis in affected tissues that utilizes antibody directed against cell-wall and capsule components. This test is unaffected by prior administration of antibiotics or formalin fixation (see References: Guarner 2003, Shieh 2003). IHC is not widely available, but requests for testing can be made through the LRN.
• Molecular subtyping (multilocus variable-number tandem repeat analysis [MLVA]), is used by the CDC and others for strain identification and tracking (see References: CDC: Approved tests for the detection of Bacillus anthracis in the LRN; Keim 1999; Keim 2000; Hoffmaster 2002: Molecular subtyping of Bacillus anthracis and the 2001 bioterrorism-associated anthrax outbreak, United States). Applications of single nucleotide polymorphism (SNP) and MLVA have also been used to discriminate closely related B anthracis isolates during outbreaks in animals. The combined SNP-MLVA analysis may hold promise for use in forensic investigations (see References: Kenefic 2008).

Antimicrobial susceptibility testing (performed at LRN reference laboratories) should be performed on clinical isolates.

• National Committee for Clinical Laboratory Standards (NCCLS) standard protocols for broth microdilution have been used with staphylococcal breakpoints.
• Concerns about penicillin use hinge on potential inducible penicillinases and poor penetration into macrophages (see References: Bell: Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax).

Serologic testing can be used for retrospective diagnosis.

• During the 2001 anthrax outbreak, the CDC developed, optimized, and qualified an enzyme-linked immunosorbent assay (ELISA) for IgG antibodies to B anthracis protective antigen (PA) (see References: Quinn 2002). The diagnostic sensitivity of the assay was 97.8% and the diagnostic specificity was 97.6%; a competitive inhibition anti-PA IgG ELISA enhanced the diagnostic specificity to 100%.
• Serum should be collected at 0 to 7 days for acute-phase testing and at 14 to 28 days for convalescent-phase testing.
• Development of measurable antibodies in recent cases required 10 to 16 days after onset of overt disease, but peak IgG levels may not be seen until 40 days after symptom onset (see References: Bell: Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax).
• Requests for serologic testing can be made through the LRN.
• The Anthrax QuickELISA, a simplified lateral-flow immunochromatographic assay for anthrax antibody, has received FDA approval from the Food and Drug Administration (FDA). The test, developed by Immunetics in collaboration with the CDC, has a diagnostic sensitivity and specificity of 100%, and is commercially available. Positive results on paired sera (-/+ or +/+) should be sent to the CDC for quantitative confirmation (see References: Biagini 2006; CDC: CDC collaboration yields new test for anthrax; Stephenson 2004).

Other tests for detection of B anthracis infection:

• A skin test for delayed-type hypersensitivity to anthrax antigen has been widely used in the former Soviet Union since 1962 for retrospective diagnosis of human and animal anthrax infection and for vaccine evaluation. An 81.5% positivity rate has been reported during the first 3 days of disease; this increases to 97% to 99% within the next 2 to 3 weeks. Anthraxin, as the product is called, is not available in the United States and has not been evaluated in this country (see References: Pfisterer 1991; Shlyakhov 1996; WHO: Guidelines for the surveillance and control of anthrax in humans and animals).

Antimicrobial Susceptibility Studies

Several recent studies have examined antimicrobial susceptibilities of B anthracis strains to various antibiotics. Data from four such studies are shown in the table below. Naturally occurring ciprofloxacin or doxycycline resistance has not been described, but isolates resistant to each of these antibiotics have been acquired in vitro (see References: Brook 2001, Price 2003). Because resistance can be induced relatively rapidly in vitro, close monitoring of patients treated for anthrax is important (see References: Athamna 2004).

MICs of Various Antibiotics for Bacillus anthracis Isolates as Identified in Four Studies
	STUDYa
	Mohammed 2002		Coker 2002		Cavallo 2002		Turnbull 2004
Antibiotic	MIC rangeb	S-I-R (%)c	MIC rangeb	S-I-R (#)c	MIC rangeb	S-I-R (%)c	MIC ranged	S-I-R (%)c
Amoxicillin					0.125-16	88.5-0-11.5
Amoxicillin–clavulanic acid							0.016-0.5	100-0-0
Azithromycin							1-12	26-64-10
Aztreonam					1->128	0-0-100
Cefaclor			0.125-0.75	25-0-0
Cefotaxime							3-32	1-0-99
Cefoxitin					1-64	74-15.3-10.7
Ceftriaxone	4-32	22-78-0			4-64	1-100-0
Cefuroxime			6-48	1-19-5
Cephalexin			0.38-2	25-0-0
Cephalothin					0.125-32	83.2-12.2-24.6
Chloramphenicol	2-8	100-0-0			1-4	100-0-0
Ciprofloxacin	0.03-0.12e	100-0-0 e	0.032-0.38	25-0-0	0.03-0.5	100-0-0	0.032-0.094	100-0-0
Clindamycin	<0.5-1	94-6-0			0.125-1	100-0-0
Doxycycline			0.094-0.38	25-0-0	0.125-0.25	100-0-0
Erythromycin	0.5-1f	3-97-0f			0.5-4	95.4-4.6-0	0.5-4	15-85-0
Gatifloxacin					0.125-0.125	100-0-0
Gentamicin					0.125-0.5	100-0-0	0.064-0.5	100-0-0
Imipenem					0.125-2	100-0-0
Levofloxacin					0.03-1	100-0-0
Nalidixic acid					0.125-32	94.8-4.2-1
Ofloxacin					0.06-2	99-1-0
Penicillin	<0.06 -128	97-0-3	<0.016-0.5	22-0-3	0.125-16	88.5-0-11.5	<0.016->32	97-0-3
Pefloxacin					0.03-1	100-0-0
Piperacillin					0.25-32	99-1-0
Rifampin	<0.25-0.5	100-0-0			0.125-0.5	100-0-0
Streptomycin					0.5-2	100-0-0
Teicoplanin					0.125-0.5	100-0-0
Tetracycline	0.03-0.06	100-0-0					0.016-0.094	100-0-0
Tobramycin			0.25-1.5	25-0-0
Vancomycin	0.5-2	100-0-0			0.25-2	100-0-0	0.75-5	99-1-0
Abbreviation: MIC, minimum inhibitory concentration. aSee References: Cavallo 2002, Coker 2002, Mohammed 2002; Turnbull 2004. bMIC values in mcg/mL. cCategorical interpretation: susceptible (S), intermediate (I), and resistant (R); expressed as percent of isolates (%) or number of isolates (#), per author preference. (Note: Standard interpretive criteria for B anthracis have not been established.) dMIC determination by Etest. eA subset of 20 isolates were tested and found to be susceptible to clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin. fA subset of 20 isolates were also tested to clarithromycin (MIC range: 0.12-0.25 mcg/mL), azithromycin (MIC range: 1-2 mcg/mL), and doxycycline (MICs = <0.015 mcg/mL).

Multiple new antifolate compounds (multiple 2, 4-diaminopyrimidine derivatives, a class of compounds with dihydrophthalazine side chains) have demonstrated in vitro activity against trimethoprim (TMP)–resistant B anthracis and have the potential to become the basis of clinically important antibacterial therapies (see References: Barrow 2007).

Tests for Exposure

Nasal swab cultures were used in the 2001 US outbreak as an epidemiologic tool to assess exposure to inhalational anthrax. In one study of 625 persons potentially exposed to anthrax spores in the Hart Senate Building, nasal swabs were positive in 28 (4.5%) (see References: Hsu 2002).

• All positive swabs were identified from persons who were in the immediate exposure area during the hour after the contaminated letter was opened. Seventy-one persons were in the exposure area during this time; therefore, the percentage of positive swabs among this group was 39% (28 of 71). Swabs from the 71 persons who were in the immediate area were obtained the day of exposure.
• Swabs collected from persons other than those in the immediate area were collected 4 days after exposure; all were negative.
• All exposed persons were placed on antimicrobial therapy and repeat nasal swaps obtained 7 days later were negative. Results of serologic testing at 7, 21, and 42 days after exposure were negative for all exposed persons.

Another study at a worksite where a contaminated letter was opened demonstrated that two (<1%) of 1,076 nasal swabs taken from potentially exposed persons were positive; however, these swabs were obtained about 13 days after exposure (see References: Traeger 2002). Similarly, all nasal swabs collected 9 to 10 days after exposure from 3,110 postal employees at a Washington, DC, postal facility that handled contaminated mail were negative (see References: Dewan 2002). These findings, along with the findings from nasal swab testing of persons exposed in the Hart Senate Building, suggest that early collection of nasal swabs results in a higher yield of positive tests.

Because the sensitivity, specificity, and predictive value of nasal swab cultures is not known, nasal swabs are not recommended for use in the clinical setting. According to the CDC (see References: CDC: Interim guidelines for investigation of and response to Bacillus anthracis exposures), collection of nasal swabs is not indicated to:

• Diagnose anthrax
• Determine risk of exposure and the need for antimicrobial prophylaxis
• Determine when antimicrobial prophylaxis should be stopped
• Supplement random environmental sampling

Although nasal swabs should not be used to determine the need for antimicrobial prophylaxis, if a swab is performed for some reason and is positive, then the patient should receive a course of postexposure antibiotics, since a positive nasal swab indicates exposure to aerosolized B anthracis (see References: Inglesby 2002). Methods for collection, labeling, transport, and processing of swabs have been published (see References: CDC/ASM/APHL 2002).

Serologic testing does not appear to be a useful tool for assessing asymptomatic exposure to B anthracis (see References: Dewan 2002, Hsu 2002, Traeger 2002).

Back to top

Treatment and Postexposure Prophylaxis

Anthrax countermeasures include antibiotics (for treatment and postexposure prophylaxis [PEP]) and vaccine. The tables below review current treatment recommendations for clinical disease caused by B anthracis.

Protocol for Treatment of Inhalational, Gastrointestinal, and Oropharyngeal Anthraxa
Patient Category	Initial IV Therapyb,c	Oral Regimens (continue therapy for 60 days [IV and PO combined])
Adults	Ciprofloxacin, 400 mg every 12 hr or Doxycycline, 100 mg every 12 hre    and One or two additional antimicrobials (agents with in vitro activity include rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, imipenem, clindamycin, and clarithromycin)f	Patients should be treated with IV therapy initially.d Treatment can be switched to oral therapy when clinically appropriate: Ciprofloxacin, 500 mg PO twice daily or Doxycycline, 100 mg PO twice daily
Children	Ciprofloxacin, 10-15 mg/kg every 12 hr, not to exceed 1 g/dayg or Doxycyclinee,h: >8 yr and >45 kg: 100 mg every 12 hr >8 yr and <45 kg: 2.2 mg/kg every 12 hr <8 yr: 2.2 mg/kg every 12 hr    and One or two additional antimicrobials (see agents listed under therapy for adults)f	Patients should be treated with IV therapy initiallyd Treatment can be switched to oral therapy when clinically appropriate: Ciprofloxacin, 10-15 mg/kg PO every 12 hr, not to exceed 1 g/day or Doxycyclineh: >8 yr and >45 kg: 100 mg PO every 12 hr >8 yr and <45 kg: 2.2 mg/kg PO every 12 hr <8 yr: 2.2 mg/kg PO every 12 hr
Pregnant womeni	Same as for nonpregnant adults (high death rate from the infection outweighs risk posed by antimicrobial agent)	Patients should be treated with IV therapy initially.§ Treatment can be switched to PO when clinically appropriate. Oral therapy regimens are the same as for nonpregnant adults.
Immunocompromised persons	Same as for nonimmunocompromised persons and children.	Same as for nonimmunocompromised persons and children.
Abbreviations: IV, intravenously; PO, orally. aMeningitis involvement must be assumed in all systemic infections. Antibiotic selection must consider penetration across blood-brain barrier (see References: Stern 2008). These treatment recommendations were made during US 2001 anthrax outbreak. In other situations, antimicrobial susceptibility testing should be used to guide therapy decisions. bCiprofloxacin or doxycycline should be considered an essential part of first-line therapy for inhalational anthrax. cSteroids may be considered an adjunct therapy for patients with severe edema (see References: Doust 1968) and for meningitis based on experience with bacterial meningitis of other etiologies. dInitial therapy may be altered based on clinical course of patient; one or two antimicrobial agents (eg, ciprofloxacin or doxycycline) may be adequate as patient improves. eIf meningitis is suspected, doxycycline may be less optimal because of poor central nervous system penetration. fBecause of concerns of constitutive and inducible beta-lactamases in B anthracis isolates, penicillin and ampicillin should not be used alone. Consultation with an infectious disease specialist is advised. Other agents with in vitro activity include tetracycline, linezolid, macrolides, aminoglycosides, and cefazolin (see References: Inglesby 2002). B anthracis strains are naturally resistant to sulfamethoxazole, trimethoprim, cefuroxime, cefotaxime sodium, aztreonam, and ceftazidime (see References: Inglesby 2002). gIf intravenous ciprofloxacin is not available, oral ciprofloxacin may be acceptable because it is rapidly and well absorbed from gastrointestinal tract with no substantial loss by first-pass metabolism. Maximum serum concentrations are attained 1-2 hr after oral doing but may not be achieved if vomiting or ileus is present. hAmerican Academy of Pediatrics recommends treatment of young children with tetracyclines for serious infections (eg, Rocky Mountain Spotted Fever). iAlthough tetracyclines are not recommended for pregnant women, their use may be indicated for life-threatening illness. Adverse effects on developing teeth and bones are dose-related; therefore, doxycycline might be used for a short time (7-14 days) before 6 months of gestation. Adapted from CDC 2001. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001; Stern 2008 (see References).

A systematic review of inhalation anthrax cases identified between 1900 and 2005 reported the following observations with regard to treatment (see References: Holty 2006).

• Initiation of therapy with antibiotics or anthrax antiserum during the prodromal phase was associated with improved survival.
• Patients who progressed to the fulminant phase, regardless of therapy, had a very high case-fatality rate (97%).
• Multidrug antibiotic therapy and pleural fluid drainage were associated with decreased mortality; however, since these modalities were predominantly used during the 2001 US anthrax outbreak, other confounding factors (eg, differences in patient characteristics, anthrax exposure, supportive care, antibiotic efficacy) may have contributed to enhanced overall survival.

Because mortality for inhalational anthrax remains high despite use of antibiotics, potential adjuvant therapies are being studied. Examples include gamma and alpha/beta interferon and adefovir (see References: Gold 2004, Shen 2004). As noted above, drainage of pleural fluid (through repeated throacentesis or chest tube drainage) may enhance survival in cases of inhalational anthrax (see References: Holty 2006: Systematic review: a century of inhalational anthrax cases from 1900 to 2005).

Protocol for Treatment of Cutaneous Anthraxa-c
Patient Category	Initial Therapy (Oral)d	Duratione
Adults	Ciprofloxacin, 500 mg PO twice daily or Doxycycline, 100 mg PO twice daily	60 days
Children	Ciprofloxacin, 10-15 mg/kg PO every 12 hr, not to exceed 1 g/day or Doxycyclinef: >8 yr and >45 kg: 100 mg PO every 12 hr >8 yr and <45 kg: 2.2 mg/kg PO every 12 hr <8 yr: 2.2 mg/kg PO every 12 hr	60 days
Pregnant womeng	Same as for nonpregnant adults (high death rate from the infection outweighs risk posed by antimicrobial agent)	60 days
Immunocompromised persons	Same as for nonimmunocompromised persons and children	60 days
Abbreviation: PO, orally. aThese treatment recommendations were made during the US 2001 anthrax outbreak. In other settings, antimicrobial susceptibility testing should be used to guide therapy decisions. bCutaneous anthrax cases with signs of systemic involvement, extensive edema, or lesions on the head or neck require intravenous therapy, and a multidrug approach is recommended (see table above: Protocol for Inhalational, Gastrointestinal, and Oropharyngeal Anthrax Cases). cTreatment of cutaneous anthrax does not prevent the evolution of the skin lesions; however, it usually will prevent progression to systemic disease (see References: Inglesby 2002). dCiprofloxacin or doxycycline should be considered first-line therapy. Amoxicillin (500 mg orally 3 times daily for adults or 80 mg/kg/day divided every 8 hr for children) is an option for completion of therapy after clinical improvement. Oral amoxicillin dose is based on need to achieve appropriate minimum inhibitory concentration. eIn cases of naturally occurring cutaneous anthrax, previous recommendations have indicated that treatment for 7 to 10 days is adequate; however, in the setting where inhalational exposure is also likely, treatment should be continued for 60 days. fAmerican Academy of Pediatrics recommends treatment of young children with tetracyclines for serious infections (eg, Rocky Mountain Spotted Fever). gAlthough tetracyclines and ciprofloxacin are not recommended for pregnant women, their use may be indicated for life-threatening illness. Adverse effects on developing teeth and bones are dose-related; therefore, doxycycline might be used for a short time (7-14 days) before 6 mo of gestation. Adapted from CDC. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001 (see References).

 

Treatment of Anthrax Meningitis

Anthrax meningitis is treated in similar fashion to inhalational anthrax, although initial treatment should include an intravenous (IV) fluoroquinolone and not doxycycline, because doxycycline has poor central nervous system (CNS) penetration. In addition to an IV fluoroquinolone, one or two other agents that have good CNS penetration and activity against B anthracis should be added (ie, penicillin, ampicillin, merpenem, vancomycin, rifampin) (see References: Sejvar 2005). Case reports suggest that adding corticosteroids may be of benefit in the management of cerebral edema/inflammation (see References: Sejvar 2005).

The optimal duration of therapy is not known, but treatment should be continued for 10 to 14 days or as long as is clinically indicated.

Back to top

Postexposure Prophylaxis

The CDC currently recommends 60 days of oral antimicrobial therapy in combination with a three-dose series of anthrax vaccine adsorbed (AVA) (see References: Stern 2008).

Antimicrobial therapy should be continued for at least 60 days for the following persons:

• Those exposed to an air space known to be contaminated with aerosolized B anthracis
• Those exposed to an air space known to be the source of an inhalational anthrax case
• Those along the transit path of an envelope or other vehicle containing B anthracis that may have been aerosolized (eg, a postal sorting facility in which an envelope containing B anthracis was processed)
• Unvaccinated laboratory workers exposed to confirmed B anthracis cultures in situations where aerosolization is suspected

Antimicrobial prophylaxis is not indicated for the following:

• Prevention of cutaneous anthrax
• Autopsy personnel examining bodies infected with anthrax when appropriate isolation precautions and procedures are followed
• Hospital personnel caring for patients with anthrax
• Persons who routinely open or handle mail (in the absence of a suspicious letter or credible threat)

The decision to prescribe PEP to asymptomatic persons in the setting of an outbreak of inhalational anthrax should be based on the likelihood of exposure and not on nasal swab testing (see Laboratory Diagnosis: Tests for Exposure above).

In the event of a mass exposure, local and state public health agencies would rapidly make antibiotics available to the exposed population (see the section below on Mass Exposure Events).

The FDA has approved several antimicrobial agents for use as anthrax PEP (see References: FDA: Doxycycline and penicillin G procaine administration for inhalational anthrax [post-exposure]; FDA: Levaquin [levofloxacin] information; Meyerhoff 2004).

• Ciprofloxacin
• Doxycycline
• Penicillin G procaine
• Levofloxacin

Analysis of published reports suggests that development of antibiotic resistance may be less likely to occur with doxycycline than with fluoroquinolones. In addition, doxycycline is several times less expensive than most fluoroquinolones and appears in clinical studies to have similar efficacy in most scenarios (see References: Brouillard 2006).

Other antimicrobial agents, including clindamycin, chloramphenical, rifampin, vancomycin, and other fluoroquinolones, may be considered for off-label use in patients unable to tolerate FDA-approved antimicrobial agents for PEP (see References: Stern 2008). Athamna and colleagues found that the combination of rifampin and clindamycin demonstrated a synergistic effect in vitro against two strains of B anthracis (see References: Athamna 2005). A number of other combinations were either indifferent or antagonistic.

The CDC recommendations for PEP (those issued during the 2001 bioterrorism anthrax attack as well as later modifications) are outlined in the table below.

Initial CDC Recommendations for PEP for Prevention of Inhalational Anthrax Following Exposure to Bacillus anthracis
Patient Category	Initial Therapy	Durationa
Adults (including immunocompromised patients)	Ciprofloxacin, 500 mg PO twice daily or Doxycycline, 100 mg PO twice daily or Levofloxacin, 500 mg PO every 24 hr [Note: Levofloxacin is FDA-approved for PEP for inhalational anthrax in adults >18 years; however, data on the safety of using levofloxacin beyond 28 days are limited. Therefore, levofloxacin is recommended as a second-line PEP agent, to be reserved for instances where medical issues call for its use (see References: FDA: Levaquin [levofloxacin] information; Stern 2008).]	60 days
Pregnant women and breastfeeding mothers	Ciprofloxacin, 500 mg PO twice daily (First-line oral agent for PEP in pregnant women.) or Doxycycline, 100 mg PO twice daily (In pregnant women, doxycycline should be used only during the third trimester.) [Note: Amoxicillin, 500 mg orally three times daily, may be used if isolate involved in exposure is determined to be susceptible to penicillinb-d]	60 days
Children (including immunocompromised patients)	Ciprofloxacin, 10-15 mg/kg PO every 12 hr, not to exceed 1 gm/day or Doxycycline: >8 yr and >45 kg: 100 mg PO twice daily >8 yr and <45 kg: 2.2 mg/kg PO twice daily <8 yr: 2.2 mg/kg PO twice daily [Note: Amoxicillin, 80 mg/kg/day divided every 8 hr not to exceed 500 mg/dose, may be used if the isolate involved in exposure is determined to be susceptible to penicillinc] or Levofloxacin, 500 mg PO every 24 hr for children >50 kg, or 8 mg/kg twice daily (not to exceed 250 mg per dose) for pediatric patients <50 kg. [Note: In May 2008, the FDA approved the use of levofloxacin for PEP for inhalational anthrax in children. As noted above for adults, data on the safety of using levofloxacin beyond 28 days are limited. In addition, levofloxacin may cause an increase in musculoskeletal adverse events in children (see References: FDA: Levaquin [levofloxacin] information).]	60 days
Abbreviation: PEP, postexposure prophylaxis; PO, orally. aRecommended in combination with a 3-dose series of AVA, BioThrax (BioPort Corp, Lansing, MI) administered at time zero, 2 weeks, and 4 weeks. AVA is not FDA-approved for PEP and, therefore, would be available under an Investigational New Drug (IND) protocol (see References: Stern 2008). After the 2001 attack, exposed persons were subsequently given the option to take an additional 40 days of antibiotics with or without anthrax vaccine; see comments below. Other antimicrobial agents, including clindamycin, chloramphenical, rifampin, vancomycin, and other fluoroquinolones, may be considered for off-label use in patients unable to tolerate FDA-approved antimicrobial agents for PEP (see References: Stern 2008). bSee comments below from American College of Obstetricians and Gynecologists regarding use of amoxicillin. cAmoxicillin is not approved by the FDA for PEP or treatment of anthrax; however, the CDC has indicated that it could be used for pregnant women or children for PEP if the isolate is determined to be susceptible. In such situations, amoxicillin could be provided under an IND or under an Emregency Use Authorization in a declared emergency (see References: CDC: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax; CDC: Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis; Stern 2008). A study to evaluate the pharmacokinetics of amoxicillin during pregnancy and postpartum found that drug concentrations adequate to prevent anthrax may be difficult to achieve during pregnancy and in the postpartum period (see References: Andrew 2007). Amoxicillin given to pediatric patients <40 kg should yield adequate time above the minimum inhibitory concentration for susceptible B anthracis (0.5 mcg/mL) over most of the dosing interval (see References: Alexander 2008) dAmerican Academy of Pediatrics considers ciprofloxacin and tetracyclines to usually be compatible with breastfeeding because the amount of either drug absorbed by infants is small, but little is know about the safety of long-term use. Therefore, amoxicillin may be considered an alternative for breastfeeding mothers if the isolate causing exposure is known to be susceptible to penicillin. Alternatively, mothers could consider expressing and discarding breast milk during therapy with ciprofloxacin or doxycycline and resuming breastfeeding after therapy is complete. Adapted from CDC 2001. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy; Stern 2008 (see References).

More than 10,000 people were placed on PEP during the 2001 anthrax outbreak; no cases of anthrax occurred among this group (see References: CDC: CDC responds: an update on treatment options for postal and other workers exposed to anthrax).

• A follow-up study of those persons who were offered antimicrobial prophylaxis demonstrated that 5,343 took at least one dose of antimicrobial therapy (see References: Shepard 2002). Of this group, 3,032 (57%) reported adverse events during the first 60 days of therapy. Gastrointestinal complaints (nausea, vomiting, diarrhea, stomach pain) were reported by 44% of those with adverse events and neurologic symptoms (headache, dizziness, light-headedness, fainting, and seizures) were reported by 33%. Fewer than half of respondents (2,712 [44%]) reported taking antimicrobial prophylaxis for at least 60 days. Of the 2,631 persons who stopped therapy before 60 days, 43% stopped because of adverse events, 25% stopped because of a low perceived risk of anthrax, and 7% stopped because of concern about long-term side effects of prolonged antimicrobial therapy.
• A statistical model was used to estimate the number of anthrax cases prevented among about 5,000 persons placed on prophylaxis who were potentially exposed to airborne anthrax spores at one of three locations (the media center in Florida, the two postal facilities in New Jersey, and the postal facility in Washington, DC). The model suggested that about nine cases were prevented through the use of postexposure antibiotics (see References: Brookmeyer 2002).

The American College of Obstetricians and Gynecologists (ACOG) has recommended the following for anthrax prophylaxis in pregnant women (see References: ACOG):

• Prophylactic treatment should be limited to women who have been exposed to confirmed environmental contamination or a high-risk source as determined by public health authorities.
• Pregnant women who have been exposed to anthrax should be started on a 60-day course of ciprofloxacin.
• Therapy should be switched to amoxicillin if the strain is found to be penicillin-sensitive.

According to ACOG, doxycycline use in pregnant women generally should be avoided because it can cause problems in fetuses, including staining of teeth and impeded bone growth; however, doxycycline should be used for exposed pregnant women who are allergic to amoxicillin and ciprofloxacin, since the risk of anthrax outweighs any potential risks to the fetus from doxycycline.

New Therapeutic Approaches

In addition to available treatment protocols, a variety of promising new therapeutic approaches for treatment of anthrax are being researched; many involve use of monoclonal antibodies (see References: Borio 2005). An alternative to monoclonal antibodies is antisera from previously vaccinated persons undergoing serial plasmapheresis. Hyperimmune plasma and immune globulin isolated in this way could potentially serve as the basis for new therapeutic treatments (see References: Pittman 2005).

• The Department of Health and Human Services (HHS) recently awarded a contract to Human Genome Sciences Inc (HGS) of Rockville, Maryland, to provide the US government with 10 grams of ABthrax (raxibacumab), a human monoclonal antibody for treating anthrax (see December 19, 2005, CIDRAP News Story). In June 2006, HHS announced that it would purchase 20,000 treatment courses of ABthrax (see References: HHS 2006: HHS to acquire new anthrax therapeutic treatment). In February 2009, HGS began delivery of the first 20,000 doses of ABThrax (see References: Human Genome Sciences 2009).
• Similarly, HHS has contracted with Cangene (a company based in Winnipeg, Manitoba) to supply anthrax immune globulin (AIG) for preliminary efficacy testing. The company describes AIG as a hyperimmune product for treating or preventing inhalational anthrax. In July 2006, HHS announced that it will purchase 10,000 treatment courses of AIG from Cangene (see References: HHS 2006: HHS to acquire anthrax immune globulin for stockpile).

Back to top

Anthrax Vaccination

Current Anthrax Vaccine

• AVA (Biothrax), manufactured by BioPort, a subsidiary of Emergent BioSolutions in Lansing, Michigan, is the only licensed human anthrax vaccine in the United States (see References: Emergent BioSolutions: Package insert).
• Most AVA vaccine has been used by the US military and vaccine is not available to the general public (except through public health officials during an anthrax emergency as part of the Strategic National Stockpile).
• AVA is prepared from cell-free infiltrates of microaerophilic cultures of an avirulent, nonencapsulated strain of B anthracis. The final product contains no live or dead bacteria.
• The final product is formulated to contain 1.2 mg/mL aluminum, added as aluminum hydroxide in 0.85% sodium chloride.
• The final product is formulated to contain 25 mcg/mL benzethonium chloride and 100 mcg/mL formaldehyde, added as preservative.

Vaccine Efficacy

• The efficacy of AVA is based on several animal studies, one controlled human trial, and immunogenicity data from humans and other mammals (see References: Brachman 1962, Gladstone 1946, Mahlandt 1966, Turnbull 1986). One study demonstrated that vaccination of adults induced an immune response in 83% of vaccinees 2 weeks after the first dose and in 91% of vaccinees who received two or more doses (see References: Turnbull 1986). Approximately 95% of vaccinees seroconverted after three doses. However, the correlation between antibody titer and protection against infection has not been defined.
• Analysis of serum from vaccinees and clinical anthrax patients shows that vaccination with three AVA injections and anthrax infection both elicited anti-PA, IgG1, IgG2 and IgG3 subclass responses (see References: Semenova 2007). One study suggests that AVA-induced antibodies to PA are sufficient to neutralize toxin activity and that AVA-induced LF and EF antibodies do not contribute to anthrax toxin neutralization in humans (see References: Taft 2008).
• Duration of efficacy is unknown, although data from animal studies suggest that it may be 1 to 2 years after two doses. Studies of military personnel vaccinated during the 1990-1991 Gulf War indicate that antigen-specific T-cell recall responses present in the circulation are comparable in magnitude to those of tetanus-diphtheria toxoids (see References: Allen 2006).
• Anthrax vaccines intended for animals should not be used in humans.

Recommendations for Use

Preexposure vaccination. Preexposure immunization with AVA is licensed for individuals aged 18 to 65 who have a high likelihood of coming into contact with B anthracis (see References: CDC: Use of anthrax vaccine in the United States). The vaccine is not licensed for children because no studies have been conducted in the pediatric population; however, the vaccine probably is safe and efficacious in children, based on experience with other inactive vaccines (see References: Inglesby 2002).

Preexposure vaccination is indicated for the following groups (see References: CDC: Use of anthrax vaccine in the United States; CDC: Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices):

• Laboratory personnel engaged in work involving production of quantities or concentrations of B anthracis cultures
• Laboratory personnel handling environmental specimens (especially powders) and performing confirmatory testing for B anthracis in LRN reference laboratories and above
• Workers who will be making repeated entries into known B anthracis-spore-contaminated areas after a terrorist attack
• Persons who come in contact in the workplace with imported animal hides, furs, bone meal, wool, animal hair, or bristles in areas where current standards and restrictions are insufficient to prevent exposure to anthrax spores
• Veterinarians and other high-risk persons handling potentially infected animals in areas of the world that have a high incidence of anthrax cases (Note: The incidence of anthrax in the United States is low; therefore, routine vaccination of US veterinarians is not recommended)
• Military personnel and other select populations who have a risk for exposure to weaponized B anthracis. After a lapse due to legal action, the Department of Defense (DoD) has resumed mandatory vaccinations for military personnel, essential DoD civilians, contractors stationed in the Middle East and South Korea, and units involved in homeland bioterrorism defense (see References: DoD 2006 and see Oct 19, 2006, CIDRAP News story).

Laboratory workers using standard Biosafety Level 2 practices are not considered by ACIP to be at increased risk for exposure to B anthracis spores.

Postexposure vaccination. Recent ACIP guidelines state that anthrax vaccine can be used in combination with antibiotics following inhalational exposure to anthrax (see References: CDC: Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices):

• Exposed persons should receive a three-dose regimen of vaccine (0, 2, and 4 weeks following exposure) and at least a 30-day course of antimicrobial therapy. Persons who do not receive vaccine should take antimicrobial therapy for at least 60 days.
• Anthrax vaccine is not currently licensed for postexposure use, so it must be given under an investigational new drug (IND) application with the FDA.

Dosage, Route of Administration, and Vaccination Schedule

Each vaccine dose is 0.5 mL. The current vaccination schedule consists of a primary series of two intramuscular injections followed by three booster intramuscular injections as outlined in the table below. In December 2008, the Food and Drug Administriation approved a change in the primary series from three doses subcutaneously (0, 2, and 4 weeks) to two doses intramuscularly (0 and 4 weeks). The Advisory Committee on Immunization Practices [ACIP] supported this change in February 2009 (see February 25 CIDRAP News Story). The change is based on a randomized, phase 4 trial, which found that a three-dose intramuscular schedule provided similar immunologic priming by month 7 compared with a four-dose subcutaneous regimen. An intramuscular route also significantly reduced the occurrence of injection-site adverse events (see References: Marano 2008).

To maintain immunity among those with anticipated ongoing exposure, the manufacturer recommends an annual booster injection using the same dosage and route after completion of the primary and booster series.

Schedule for Anthrax Vaccinationa
Primary series (2 injections)	Week 0 Week 4
Booster series (3 injections)b	6 mo after primary series 12 mo after primary series 18 mo after primary series
aAll doses are 0.5 mL and should be given intramuscularly. bAdditional boosters to be given annually (same route and dose) for those at ongoing risk of exposure.

Contraindications and Precautions

• The main contraindication is a history of anaphylaxis after receiving a dose of AVA or any of the vaccine components.
• History of anthrax disease may increase the potential for severe local adverse reactions.
• If BioThrax is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished.
• AVA is labeled as Pregnancy Category D (see References: Emergent BioSolutions: Package insert). According to the manufacturer's package insert, "Pregnant women should not be vaccinated against anthrax unless the potential benefits of vaccination have been determined to outweigh the potential risk to the fetus."
• Few studies have been published regarding the use of anthrax vaccine in pregnant women.
• A recent study among US army women demonstrated that anthrax vaccine had no effect on subsequent pregnancies, birth rates, or adverse birth outcomes, although the power to detect adverse birth outcomes in the cohort was limited (see References: Wiesen 2002).
• A retrospective cohort study evaluated birth defects in relation to maternal anthrax vaccination for infants born to US military service women from 1998 through 2004. Among 115,169 infants born to military women during this period, 37,140 were born to women ever vaccinated, and 3,465 were born to women vaccinated in the first trimester of pregnancy. Birth defects were slightly more common among infants born to women vaccinated during the first trimester compared with infants born to women vaccinated beyond the first trimester; however, this finding was not statistically significant. An analysis of infants born to women vaccinated in the first trimester and infants born to women who were never vaccinated found that birth defects were slightly higher (odds ratio = 1.2; 95% confidence interval = 1.02 to 1.42) in the vaccinated group (see References: Ryan 2008).

Adverse Reactions

• Injection site adverse reactions are the most common and occur in more than half of vaccine recipients. These include warmth, tenderness, itching, erythema, induration, edema, and nodule formation. Most local adverse reactions are mild or moderate in severity.
• Systemic reactions (fever, chills, myalgia, nausea) following vaccination may occur in 10% to 25% of recipients.
• One report identified five cases of new-onset rheumatoid arthritis (RA) temporally related to anthrax vaccine. The most recent occurred in a 42-year-old man who experienced knee and interphalangeal joint stiffness and pain 5 days after receiving the first dose of anthrax vaccine. Serologic and radiologic examinations revealed mild degenerative changes in his hands and knees bilaterally (see References: Vasudev 2006). It is unclear at this time whether or not these case reports represent a true association between anthrax vaccination and RA, since this issue has not been systematically evaluated.

Postlicensure Adverse Event Reporting

• Between 1990 and 2000, the Vaccine Adverse Event Reporting System (VAERS) received 1,544 reports of adverse events following anthrax vaccination (see References: CDC: Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices). The most frequent adverse events reported include injection site hypersensitivity (334), injection site edema (283), injection site pain (247), headache (239), arthralgia (232), asthenia (215), and pruritus (212).
• Review of anthrax vaccination data from a 1967 to 1972 study and medical literature from 1955 to 2005 suggests that women have at least twice the risk of having a vaccine reaction compared with men. The age adjusted relative risk for injection site reaction was 2.78 (95% confidence interval, 2.29 to 3.38) (see References: McNeil 2007: Short-term reactogenicity and gender effect of anthrax vaccine).
• Between December 15, 1997, and April 12, 2000, 425,976 service members received 1,620,793 doses of AVA. As of April 7, 2000, 428 VAERS reports had been received through the Department of Defense (see References: CDC: Surveillance for adverse events associated with anthrax vaccine). Of these, 311 (72.7%) concerned system reactions, 78 (18.2%) were reports of mild or moderate local reactions, and 39 (9.1%) were for large or complicated local reactions. As of March 21, 2000, a panel of civilian scientific and medical experts had not identified any pattern of adverse events among 674 reports that had been reviewed. Comparative analysis of immunization records in the military VAERS reports and the Defense Medical Surveillance System suggest that the information contained in both sets of records is similar for anthrax and for nonanthrax vaccine immunizations (see References: McNeil 2007: A comparative assessment of immunization records).
• Some reports have suggested an association between optic neuritis and anthrax vaccination (or receipt of other vaccines). However, a matched case-control study among US military personnel from Jan 1, 1998, through Dec 31, 2003, revealed no significant associations between optic neuritis and anthrax vaccination (see References: Payne 2006).

Development of New Vaccines

Research into new anthrax vaccines is ongoing. Most vaccines that have been studied utilize recombinant technology or employ new adjuvants to increase the immune response.

• Current human anthrax vaccines consist of supernatant material from cultures of a toxigenic, nonencapsulated strain of B anthracis. Second-generation vaccines using recombinant protective antigen (rPA) are being developed as an alternative, as much of the immunogenicity of the current vaccine arises from this protein component (see References: Helper 2006, Rhie 2005).
• Emergent Biosolutions, Inc (maker of the current anthrax vaccine) is studying a new candidate vaccine (AV7909), which comprises BioThrax (Anthrax Vaccine Adsorbed) in combination with the immunostimulatory compound CPG 7909 as an adjuvant (see References: Emergent BioSolutions: Press release).
• One study suggests that oral, live, attenuated, spore-based vaccines could offer long-lasting protection against anthrax in humans (see References: Aloni-Grinstein 2005). The investigators administered a previously described live, attenuated, nontoxinogenic, nonencapsulated B anthracis spore vaccine orally to guinea pigs and found that protective immunity correlated with development of a threshold level of PA neutralizing antibody titers. Protective immunity also appeared to be long-lasting.
• Several animal studies have shown that the presence of EF (edema factor) in vaccine preparations can promote protective immunity against anthrax, and inclusion of EF in multicomponent subunit vaccines is a consideration (see References: Quesnel-Hellmann 2006, Zeng 2006).
• Combination vaccines such as one against anthrax and plague may represent the next generation of vaccines against potential agents of bioterrorism (see References: DuBois 2007).

Back to top

Management of Exposure Events

Potential Types of Exposures

The most likely methods of exposure to weaponized anthrax spores include:

• Localized exposure to a white powder (such as a contaminated letter or package sent through the mail)
• Contamination of a closed air supply (such as the ventilation system of a building)
• Broad contamination of outdoor air (such as release of anthrax spores via a crop duster or similar aircraft)
• Contamination of a commercial food or beverage source (which would cause gastrointestinal or oropharyngeal disease)

Only exposure to a white powder would be recognized at the time of the event. The other methods of exposure most likely would not be recognized until cases of disease occurred (unless indoor or outdoor air-monitoring systems are in place and capable of detecting B anthracis spores with some degree of sensitivity).

Back to top

Handling of Suspicious Packages

According to the US Postal Service, suspicious letters or packages should not be opened (see References: US Postal Service). A letter or package should be considered suspicious if it:

• Has any powdery substance on the outside
• Is unexpected or from someone unfamiliar to you
• Has excessive postage, a handwritten or poorly typed address, an incorrect title or a title with no name, or misspellings of common words
• Has no return address or one that can't be verified as legitimate
• Is of unusual weight, given its size, or is lopsided or oddly shaped
• Has an unusual amount of tape
• Is marked with restrictive endorsements, such as "Personal" or "Confidential"
• Has a strange odor or stain

During the 2001 anthrax attacks, cases occurred among persons who opened mail and among persons who merely handled contaminated mail; therefore, suspicious packages or letters should be handled as little as possible. Recent forensic analysis has indicated that nearly 8 x 10⁶ CFU were removed from the most highly cross-contaminated piece of mail found (see References: Beecher 2006). The CDC has published specific recommendations regarding handling suspicious packages or letters (see References: CDC: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy):

• Do not shake or empty the contents of a suspicious package or envelope.
• Do not carry the package or envelope, show it to others, or allow others to examine it.
• Put the package or envelope on a stable surface; do not sniff, touch, taste, or look closely at it or any contents that may have spilled.
• Alert others in the area about the suspicious package or envelope. Leave the area, close doors, and take actions to prevent others from entering the area. If possible, shut off the ventilation system.
• Wash hands with soap and water to prevent spreading potentially infectious material to face or skin. Seek additional instructions for exposed or potentially exposed persons.
• If at work, notify a supervisor, a security officer, or a law enforcement official. If at home, contact the local law enforcement agency (ie, police).
• If possible, create a list of persons who were in the room or area when the suspicious letter or package was recognized and a list of persons who also may have handled the package or letter. Give the list to both the local public health authorities and law enforcement officials.

If a patient reports exposure to a suspicious package that contains an unknown white powder, further evaluation should be undertaken by public health and law enforcement officials.

• Recommendations for testing the package contents for B anthracis should be made on the basis of a risk assessment conducted by public health and law enforcement officials.
• If the patient is considered at risk and is asymptomatic, then antimicrobial
• prophylaxis should be initiated pending results of microbiologic testing of the package contents.
• If the patient has symptoms compatible with anthrax, then appropriate antimicrobial treatment should be administered.

A prospective longitudinal study of 124 subjects who may have been exposed to B anthracis during the anthrax attack in the US Capitol demonstrated that the significance of low-level exposure should not be underestimated (see References: Doolan 2007). The authors’ conclusion is based on the following:

• Spore exposure primed immune responses in a dose-dependent manner and may have enhanced vaccine boost and recall responses.
• Immune responses were detected among subjects inside the defined exposure zone as well as subjects outside the zone, implying more extensive spore migration than had been predicted.
• Despite the fact that subjects received PEP with antibiotics, spore inhalation provoked immune system stimulation consistent with subclinical infection (and possibly antibiotic-aborted infection after germination of viable spores); greater levels of exposure corresponded to more complete immune responses.

Mass Exposure Events

• In the event of a mass exposure, rapid delivery of prophylactic antibiotics to the exposed population would be critical to prevent illness and death (see References: Wein 2003). A recent simulation analysis suggested that postattack antibiotic therapy and vaccination of exposed individuals represents the most cost-effective strategy for a small-scale attack (see References: Schmitt 2007).
• In emergency situations involving a bioterrorist release, state governments can request antibiotic and medical supplies from the Strategic National Stockpile through the CDC; the CDC is ready to rapidly deploy the stockpile as needed and can deliver initial supplies within several hours.
• State and local health departments have bioterrorism preparedness plans in place to provide points of distribution (PODs) for mass antibiotic prophylaxis against anthrax and other biological agents as needed. During the 2001 anthrax outbreak, the New York City Department of Health and Mental Hygiene activated their incident command system and put their antibiotic distribution plan into effect. Lessons learned from this experience were published in June 2003 (see References: Blank 2003).
• One analysis suggests that the critical determinant of mortality after an anthrax bioterrorism event is local dispensing capacity (see References: Bravata 2006). Modeling suggests a higher mortality among sites with low dispensing capacities, compared with those with high dispensing capacities. Doubling local inventories at high dispensing sites makes stockpiling five-fold more cost-effective than at low dispensing sites.
• Mass prophylaxis campaigns carry the risk of overwhelming emergency health services owing to visits for actual or perceived medication-related adverse events (see References: Hupert 2007). Modeling suggets that the length of a mass prophylaxis campaign (eg, 10 days vs 2 days) plays an important role in determining the subsequent intensity in emergency services utilization due to real or suspected adverse events.

Surveillance During Exposure Events or for Early Detection of Outbreaks

Several reports have examined surveillance approaches for anthrax either in the setting of a known exposure or as an early population-based detection tool.

• During 2003, the Connecticut Public Health Department (CPHD) implemented gram-positive rod surveillance for early anthrax detection (see References: Begier 2005). The CPHD reported that this laboratory-based surveillance system is a tool that could provide early detection of even a single case of inhalational anthrax.
• During the 2001 anthrax outbreak, the New York City Department of Health and Mental Hygiene (NYC DOHMH) established the Cutaneous Anthrax Rapid Referral System (CARRS) for rapid referral and early diagnosis of anthrax cases (see References: Redd 2005). This system functioned to efficiently assess patients but also provided a mechanism for rapid centralized reporting, which could be a good surveillance model in the setting of a known mass exposure to anthrax.
• Sydromic surveillance may be a valuable tool for early detection of anthrax cases in the setting of a mass exposure where relatively large numbers of cases would be expected to occur (see References: CDC: Syndromic surveillance: reports from a national conference 2004; Nordin 2005).

Back to top

Hospital Infection Control (Including Autopsies and Burial)

Isolation Precautions

• Although people with inhalational anthrax may have had contamination of hair and clothing at the time of their exposure, residual contamination at the time of medical presentation does not appear to be of concern. Also, no secondary cases occurred among household contacts of the inhalational cases in the 2001 US outbreak.
• Standard Precautions are considered adequate for patients with inhalational, gastrointestinal, and oropharyngeal anthrax, since person-to-person transmission for these forms of disease has not been reported.
• Most sources also recommend Standard Precautions for cases of cutaneous anthrax (see References: APIC/CDC: Bioterrorism readiness plan; Inglesby 2002). However, person-to-person transmission rarely has been reported for patients with cutaneous anthrax; therefore, several sources have recommended that Contact Precautions be followed for patients who have draining cutaneous lesions (see References: Weber 2001, Swartz 2001). Contact Precautions include the following:
• Place the patient in a private room, or if a private room is not available, place the patient in a room with a patient who has an active infection with the same pathogen (ie, cohort). When a private room is not available and cohorting is not possible, a spatial separation of at least 3 ft should be maintained between the infected patient and other patients and visitors.
• Gloves should be worn when entering the room and removed before leaving the room; hands should be washed with an antimicrobial agent or a waterless handwashing agent immediately after removing gloves, and clean hands should not touch potentially contaminated items or environmental surfaces.
• Gowns should be worn when entering the room if it is anticipated that clothing will have substantial contact with the patient, environmental surfaces, or items in the room; the gown should be removed before leaving the patient's environment.
• Patient transport should be limited to essential purposes only; if the patient is transported out of the room, precautions should be maintained.
• Noncritical patient-care equipment should be dedicated whenever possible. If equipment cannot be dedicated, then it should be adequately cleaned and disinfected between patients.
• Soiled dressings should be incinerated or autoclaved.
• A recent study on the use of hand-hygiene agents to remove B atrophaeus (a surrogate of B anthracis) from contaminated hands demonstrated that use of a waterless hand rub containing ethyl alcohol was not effective in removing spores (see References: Weber 2003). Conversely, handwashing with soap and water, 2% chlorhexidine gluconate, or chlorine-containing towels reduced the level of spore contamination.

Cleaning Surfaces and Instruments

According to the CDC, the following procedures should be followed when cleaning surfaces following spills or when cleaning instruments (see References: CDC: Basic laboratory protocols for the presumptive identification of Bacillus anthracis):

• Commercially available bleach or 0.5% hypochlorite solution (a 1:10 dilution of household bleach) is considered adequate for cleaning.
• Contaminated items (eg, pipettes, needles, loops, microscope slides) should be immersed in decontamination solution until autoclaving.
• Work surfaces should be wiped down before and after use with decontamination solution.
• Spills involving fresh cultures or samples known to have low concentration of spores should be flooded with decontamination solution and soaked for 5 minutes before cleanup.
• Spills that involve samples with high concentration of spores, involve organic matter, or occur in areas of lower than room temperature (eg, refrigerators, freezers) should be exposed to decontamination solution for at least 1 hour before cleanup.
• Personnel involved in the cleanup of any spill should wear gloves, safety glasses, and a laboratory coat or gown during the cleanup process.
• Respiratory protection should be considered for spills in which a substantial aerosolization is suspected.

Personal Protective Equipment for Workers

Information regarding personal protective equipment for first responders and others with potential occupational exposure to anthrax spores can be found on the following Web pages (see References):

• CDC: Protecting investigators performing environmental sampling for Bacillus anthracis: personal protective equipment
• CDC: Interim recommendations for firefighters and other first responders for the selection and use of protective clothing and respirators against biological agents
• OSHA: Anthrax prevention and controls

Other Issues

• One study examined biocide inactiviation of B anthracis spores in the presence of food residues (see References: Hilgren 2007). The presence of food residues had only a minimal effect on peroxyacetic acid and H₂0₂ sporicidal efficacy, but the efficacy of sodium hypochlorite was markedly inhibited by whole-milk and egg yolk residue. Decontamination procedures should be adjusted to address situations for food-soiled surfaces.

Autopsy Practices

• Instruments used in autopsies should be autoclaved or incinerated.
• Recent guidelines from the CDC indicate that Standard Precautions should be used for postmortem care. These include using a surgical scrub suit, surgical cap, impervious gown or apron with full sleeve coverage, a form of eye protection (eg, goggles or face shield), shoe covers, and double surgical gloves with an interposed layer of cut-proof synthetic mesh (see References: CDC: Medical examiners, coroners, and biologic terrorism: a guidebook for surveillance and case management).
• In addition, autopsy personnel should wear N-95 respirators during all autopsies, regardless of suspected or known pathogens. Powered air-purifying respirators (PAPRs) equipped with N-95 or high-efficiency particulate air (HEPA) filters should be considered.

Burial

• Contact with corpses should be limited to trained personnel and routine precautions should be implemented when transporting corpses.
• According to the CDC, cremation is the preferred disposition method. If cremation is not possible, bodies should be "properly secured in a sealed container (eg, a Zigler cases or other hermetically sealed casket) to reduce the potential risk of pathogen transmission" (see References: CDC: Medical examiners, coroners, and biologic terrorism: A guidebook for surveillance and case management).
• According to WHO guidelines (see References: Turnbull 1998), "In fatal cases, postmortem should be discouraged; cremation is preferable to burial where local custom permits. It is advisable for the body to be placed in an impervious body bag for transport from the place of death and preferably the body should not be extracted from the bag. Where only burial is permitted, the bagged body should be placed in a hermetically sealed coffin and buried without re-opening."
• An example of the type of system that can be used to seal remains prior to placing them in a casket for burial is the Bioseal system, produced by Barrier Products, LLC (see References). This system utilizes a poly-aluminum foil–extruded laminate material that when used with a heat sealer will provide Level 1 containment for all gases, fluids, vapors, and odors associated with the transport and storage of human and animal remains.

Back to top

Environmental Testing and Decontamination

Environmental Testing as a Detection Tool

Autonomous detection systems (ADSs) have been developed to detect B anthracis spores in the environment (indoor or outdoor) as the first signal of an aerosol release. Examples include the following:

• Biohazard Detection System (BDS): The BDS is a fully automated air-sampling system consisting of an aerosol collector, PCR cartridge based on Cepheid GeneXpert technology, and controller computer. It has been deployed in mail processing and distribution centers across the United States. Positive BDS signals will be confirmed by an LRN reference or national laboratory (see References: CDC: Responding to detection of aerosolized Bacillus anthracis by autonomous detection systems in the workplace; NALC).
• According to the CDC guidelines, when a positive BDS signal occurs, the following immediate response is appropriate:
• Stop work activities.
• Stop and secure any potential aerosol-generating equipment.
• Turn off heating, ventilation, and air conditioning (HVAC) units serving the production or processing area (leave local exhaust ventilation on machines turned on).
• Notify local and federal law enforcement and public health officials.
• Immediately account for all workers to ensure their evacuation.
• Gather personal identification and contact information.
• Depending on the level of potential exposure, decontamination of employees (with removal of clothing and washing exposed areas or showering at the site) may be necessary.
• The decision to begin postexposure antibiotic prophylaxis should be made on the basis of risk of exposure, threat assessment, validity of preliminary laboratory testing, and logistics of initiating an intervention.
• Autonomous Pathogen Detection System (APDS): Consists of an aerosol collector, flow-through PCR subsystem with sequential injection analysis, and a multianalyte flow-cytometry subsystem for PCR product detection (see References: Hindson 2004, Lawrence Livermore National Laboratory 2002).
• Anthrax Smoke Detector (ASD): An automated system designed by the National Aeronautics and Space Administration (NASA) to detect changes in airborne bacterial spore concentrations, including spores of B anthracis. The system measures dipicolinic acid (DPA), a chemical marker of bacterial spores. The ASD is intended as a relatively low-cost screening tool and requires that positive signals must be confirmed by B anthracis–specific assays (see References: Lester 2004). A recent test revealed that the device had a detection limit of 16 spores/L when 250 L of air was sampled (see References: Yung 2007).
• Handheld Advanced Nucleic Acid Analyzer (HANAA). A real-time PCR analyzer utilizing a miniaturized thermal cycling process (see References: Lawrence Livermore National Laboratory 2002).
• Mobile laboratory systems (used primarily by the military): Automatic Biological Agent Testing System (ABATS), PortalShield, Joint Biological Point Detection System (JBPDS), Biological Integrated Detection System (BIDS) (see References: Fitch 2003).

Environmental Testing Following a Release

Environmental testing for B anthracis should be conducted by public health or law enforcement officials in the context of an epidemiologic or criminal investigation. Sampling should be guided by available epidemiologic data whenever possible (see References: Teshale 2002).

Criteria for performing directed sampling of environmental surfaces as specified by the CDC include the following (see References: CDC: Interim guidelines for investigation of and response to Bacillus anthracis exposures):

• To identify a site or source of B anthracis exposure that resulted in a case(s) of anthrax
• To trace the route of an exposure vehicle (eg, powder-containing letter)
• To obtain the B anthracis stain when isolates from patients are not available
• To guide cleanup activities in a contaminated area or building
• To assess biosafety procedures in laboratories processing B anthracis specimens

A protocol for collecting surface environmental samples is available on the CDC Emergency Response and Preparedness Web site (see References: CDC: Comprehensive procedures for collecting environmental samples for culturing Bacillus anthracis).

A recent report from the US Government Accountability Office (GAO) published in March 2007 recommended that federal sampling methods for anthrax detection be validated to provide confidence that test results (particularly negative results) are accurate (see References: GAO 2007). The report indicated that it is currently not clear which federal agency should take the lead in conducting the validation studies.

ASTM International (formerly the American Society for Testing and Material Standards), a voluntary standards development organization, has published a standard on practices for “bulk sample collection and swab sample collection of visible powders suspected of being biological agents from nonporous surfaces.” A recent collaborative study validated the methods in the standard and showed that high levels of B anthracis and B thuringiensis spores can be recovered from surfaces by both dry and wet swab sampling methods (see References: Locascio 2007).

Environmental sampling of a US postal facility in Washington, DC, during the 2001 anthrax outbreak demonstrated the following (see References: Sanderson 2002):

• Sampling using wipes or HEPA vacuum socks provided a better yield than sampling with wet or dry swabs.
• Dry swabs generally should not be used for sampling, since yields are so low.
• Wet swabs may be useful in certain situations (eg, crevices, inside machinery, other areas difficult to reach by wipe or HEPA vacuum samples).
• Wipes are preferable for sampling areas with light dust.
• HEPA vacuum socks should be used to sample surfaces with heavy dust.

One study evaluated four swab materials (cotton, macrofoam, polyester, and rayon) and methods of processing to determine optimal spore recovery. Results demonstrated that premoistened cotton and macrofoam swabs were the most efficient (see References: Rose 2004). In a study of polyester-rayon wipes, sonication extraction improved recovery of spores from wipes used for cleaning surfaces.The wipe recovery quantitative limits of detection were estimated at 90 colony-forming units (CFU) per unit of stainless steel surface area and 105 CFU per unit of painted wallboard (see References: Brown 2007). In a study of recovery efficiencies of anthrax spores, contact plates performed better than other methods for flat, nonporous, nonabsorbent surfaces, with recovery rates of 28% to 54%. Contact plates also performed the best on flat, porous, absorbent surfaces, although recoveries were low (less than 7%). For moistened devices (wipes, swabs, and sample collection and recovery devices), wipes were generally the best (see References: Frawley 2008).

Official procedures for testing food and water have not been published, but protocols have been reportedly developed by USAMRIID (see References: Higgins 1999) and are under development elsewhere.

Examples of commercial and investigational test kits used for environmental sampling are outlined in the table below. A study of three systems, Anthrax BioThreat Alert (BTA), BioWarfare Agent Detection Devices (BADD), and SMART II, found a minimum detection limit of 10⁵ spores, far above the level of 10² spores desired by first-responders (see References: King 2003). The specificities of these systems have not been independently evaluated.

Commercial/Investigational Anthrax-Specific Tests for Environmental Sampling

Smart IIa [Product information] Manufacturer: New Horizons Diagnostics (Columbia, Maryland)

Status: Commercially available Target: Spore antigen, unspecified Detection technology: Embedded flow immunochromatography Current use: Surfaces, powders Published evaluation: King 2003 (see References) Performance with B anthracis: Data not available Performance with non–B anthracis: Data not available Turnaround time: <5 min Detection limits: ~105 spores

Tetracore Biothreat Alert (BTA) test stripsa [Product information] Manufacturer: Alexeter Technologies (Wheeling, Illinois)

Status: Commercially available Target: Single, unspecified Detection technology: Lateral flow immunochromatography Current use: Environment Published evaluation: King 2003 (see References) Performance with B anthracis: Data not available Performance with non–B anthracis: Data not specifically available, but 7% false-positive rate has been reported (per manufacturer) Turnaround time: <15 min Detection limits: ~105 spores

CDC molecular-based assaysb Manufacturer: CDC (in-house) (Atlanta)

Status: Available through LRN, investigational Target: Sequences on pOX1, pOX2 plasmids, and one chromosomal target Detection technology: Real-time PCR; SmartCycler and LightCycler platforms Current use: Environment, clinical samples Published evaluation: Hoffmaster 2002, Hoffmaster 2002 supplement (see References) Performance with B anthracis: Tested against 81 archived isolates (1939-1997, range of MLVA types), and 317 virulent isolates from 2001 outbreak. All isolates were positive for chromosomal targets. All fully virulent isolates also were positive for both plasmid targets, and pX01- or pX02-cured isolates were negative for those respective targets (see References: Hoffmaster 2002) Performance with non–B anthracis: Tested against 56 isolates of 6 Bacillus species other than B anthracis and 88 other non–B anthracis isolates chosen on the basis of their morphological similarity to B anthracis on blood agar. Assay was negative for all targets (see References: Hoffmaster 2002) Turnaround time: <1 hr Detection limits: 5-10 spores or 1 pg purified DNA from vegetative cells (about 167 cells)

LightCycler assayb [Product information] Manufacturer: Roche Diagnostics, Mayo Clinic

Status: Investigational Target: Sequences on protective antigen gene (pagA) on pOX1 and encapsulation B protein gene (capB) on pOX2 Detection technology: Real-time PCR; LightCycler platform Current use: Not specified Published evaluation: Bell 2002 (see References) Performance with B anthracis: Tested against 31 archived isolates (origin unspecified). All fully virulent isolates were positive for both targets, and pX01- or pX02-cured isolates were negative for those respective targets (see References: Bell 2002) Performance with non–B anthracis: Tested against 31 isolates of 13 Bacillus species and 26 isolates from other genera. Test results were negative for both targets (see References: Bell 2002) Turnaround time: <1 hr Detection limits: 5 copies of target sequence per analytical reaction

R.A.P.I.D. System [Product information] Manufacturer: Idaho Technology, Inc (Salt Lake City, Utah)

Status: Commercially available Target: Lethal factor, protective antigen, unspecified Detection technology: Ruggedized real-time PCR; LightCycler platform Current use: Environmental or human sources Published evaluation: None Performance with B anthracis—manufacturer evaluation: Targets 1 and 2 tested against 29 strains, and target 3 tested against 27 strains (origin of strains unspecified). All tested positive (see References: Idaho Technology, Inc) Performance with non–B anthracis—manufacturer evaluation: Tested against 8 isolates of 2 Bacillus species other than B anthracis and 1 isolate of Clostridium botulinum. Test results were negative for all targets (see References: Idaho Technology, Inc) Turnaround time: 35 min Detection limits: 100 fg DNA (about 20 copies)

BioWarfare Agent Detection Device (BADD)a [Product information] Manufacturer: Osborne Scientific (Lakeside, Arizona)

Status: Commercially available Target: Unspecified Detection technology: Unspecified Current use: Environment Published evaluation: King 2003 (see References) Performance with B anthracis—manufacturer evaluation: Three strains tested positive (origin of strains unspecified) (see References: Osborne Scientific) Performance with non–B anthracis—manufacturer evaluation: Tested negative for 2 strains of Bacillus species other than B anthracis (see References: Osborne Scientific) Turnaround time: 15-30 min Detection limits: 0.25 mcg (1.0 mcg /mL); ~105 spores

RAMP Anthrax Test Cartridge [Product Information] Manufacturer: Jant Pharmacal Corporation (Encino, California)

Status: Commercially available Target: Unspecified Detection technology: Immunochromatographic fluorescence test Current use: Environment Published evaluation: Harper 2006 (see References) Performance with B anthracis: Powder residues containing B anthracis were sampled and tested from 7 nonporous environmental surfaces. The overall false-positive rates was 1.79% and the false-negative rate was 1.07%. Turnaround time: 15-30 min Detection limits: ~4,000 spores

Abbreviations: CDC, Centers for Disease Control and Prevention; LRN, laboratory response network; PCR, polymerase chain reaction. aCDC has published a health advisory about use of hand-held assays (see References: CDC: Hand-held immunoassays for detection of Bacillus anthracis). bSee References: CDC: FAQs about anthrax—laboratory testing.

 

Decontamination of Persons Exposed to Anthrax

According to guidelines from the Association for Professionals in Infection Control and Epidemiology and the CDC (see References: APIC/CDC):

• Patients should remove contaminated clothing and store in labeled, plastic bags.
• Clothing should be handled as little as possible to avoid agitation.
• Patients should shower thoroughly with soap and water.

Decontamination of Environments

Concerns regarding environmental contamination involve both primary and secondary aerosolization.

• Primary aerosolization occurs when the spores are first made airborne. This is the period when the risk of inhalation is the greatest.
• Secondary aerosolization involves resuspension of spores into the air after they have initially settled on environmental surfaces. The risks posed by secondary aerosolization have not been defined and are dependent on a number of variables (eg, concentration of spores in the environment, type of powder used in the suspension, level of activity in the contaminated area, type of environmental surface involved).

During the 2001 anthrax attacks, the Environmental Protection Agency (EPA) assessed the potential for secondary aerosolization inside the Hart office building by conducting environmental sampling under semiquiescent (minimal activity) conditions and under simulated active office conditions (see References: Weis 2002).

• Findings demonstrated that viable B anthracis spores could be reaerosolized during simulated active office conditions.
• CFU levels detected through air sampling demonstrated as much as a 65-fold increase under the active office conditions compared with the semiquiescent conditions.
• These findings support the need for environmental decontamination and protection of decontamination workers following release of high concentrations of anthrax spores into indoor environments.

During the 2001 US anthrax outbreak, several buildings underwent environmental decontamination to eliminate the risk of potential secondary aerosolization. In the setting of a bioterrorism attack, the EPA is charged with directing cleanup activities and providing the necessary technical expertise to guide such efforts. EPA used several methods and technologies to decontaminate buildings during the 2001 outbreak (ie, chlorine dioxide, decontamination foam, ethylene oxide). Cleanup plans generally involve the following:

• Assess the size and type of the potentially contaminated area.
• Assess how the contamination was delivered.
• Conduct sampling to determine the level of contamination.
• Determine the microbiocide to be used and methods of delivery for decontamination.
• Carry out decontamination procedures.
• Conduct environmental sampling after decontamination to assure that anthrax spores have been removed or killed and that the area is safe to reoccupy.

Until the recent anthrax attack, experience with decontamination of buildings after contamination with weapons-grade anthrax spores was limited. Questions regarding the best methods for decontamination in such situations still remain (see References: Spotts Whitney 2003). In addition, reasonable standards for cleanup effectiveness remain to be established (see References: Canter 2005). Paraformaldehyde (with B subtilis as the indicator) has been used to decontaminate laboratories.

The chlorine dioxide fumigation approach used after the 2001 postal anthrax attacks is expensive and can preclude reoccupation of contaminated buildings for many years. Wein and colleagues compared this approach to a strategy of HEPA vacuuming, HEPA air cleaners, and vaccination of building occupants (see References: Wein 2005). They found in a simulated outdoor release in lower Manhattan that the HEPA/vaccine method would require less time, cost less, and reduce solid waste problems associated with disposal of contaminated carpets and upholstery. However, the details of the massive cleanup operation modeled by the study depend on many factors related to the attack itself, which obviously cannot be accurately predicted. Furthermore, vaccination of reoccupants may not be a practical or acceptable approach.

Vaporized hydrogen peroxide (Vaprox) may represent a new method for decontamination of buildings. The EPA has granted vaporized hydrogen peroxide an emergency exemption for the specific use of anthrax decontamination. Review of data showed that the gas was effective at filling spaces and usable in any four-walled space with a ceiling. Available data showed that the gas significantly reduced bacterial spore populations under specific conditions (see References: EPA 2006).

Several hypochlorite-containing household products on the market were found to be effective in decontaminating fluid milk or similar food products contaminated by spores to allow safe disposal (see References: Black 2008). A combination of high temperature (90°C to 95°C) and hydrogen peroxide also could be used to inactivate B anthracis spores (see References: Xu 2008).

Back to top

Public Health Reporting and Case Definitions

Anthrax cases should be reported immediately to local or state health departments, according to disease reporting rules.

The anthrax case definition for public health surveillance is as follows (see References: CDC: Case definition of anthrax and summary of confirmed cases; CDC: Case definitions for infectious conditions under public health surveillance):

Clinical Description

An illness with acute onset characterized by several distinct clinical forms, including the following:

• Cutaneous: a skin lesion evolving during a period of 2 to 6 days from a papule, through a vesicle, to a depressed black eschar
• Inhalational: a brief prodrome resembling a viral respiratory illness, followed by development of hypoxemia and dyspnea, with radiographic evidence of mediastinal widening
• Intestinal: severe abdominal distress followed by fever and signs of septicemia
• Oropharyngeal: mucosal lesion in the oral cavity or oropharynx, cervical adenopathy and edema, and fever

Confirmed Cases

The CDC defines a confirmed case of anthrax as:

• A clinically compatible case of cutaneous, inhalational, or gastrointestinal illness that is laboratory-confirmed by isolation of B anthracis from an affected tissue or site or other laboratory evidence of B anthracis infection based on at least two supportive laboratory tests.

Back to top

Images

• Cutaneous anthrax images (Centers for Disease Control and Prevention)
• Cutaneous anthrax infection (Roche KJ, Chang MW, Lazarus H. N Engl J Med 2001;345[22]:1611)
• Histopathology, microbiology, skin lesions, chest x-ray findings (Public Health Image Library)
• Inhalational anthrax images (Centers for Disease Control and Prevention)
• Inhalational anthrax images: histopathology (Armed Forces Institute of Pathology)
• Inhalational anthrax images: microbiology (Armed Forces Institute of Pathology)

Back to top

References

AAP (American Academy of Pediatrics). The child with suspected anthrax exposure or infection, Dec 20, 2001 [Web page]

Abramova FA, Grinberg LM, Yampolskaya OV. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci 1993 Mar 15;90(6):2291-4 [Full text]

Abshire TG, Brown JE, Ezzell JW. Production and validation of the use of gamma phage for identification of Bacillus anthracis. J Clin Microbiol 2005 Sep;43(9):4780-8 [Full text]

ACOG. Advisory to physicians on anthrax treatment of pregnant women [Full text]

AHRQ. Pediatric anthrax: implications for bioterrorism preparedness. AHRQ Publication No. 06-E013. 2006 Aug [Full text]

Alexander JJ, Coangelo PM, Cooper CK, et al. Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations. Pediatr Infect Dis J 2008 Nov;27(11):955-7 [Abstract]

Allen JS, Skowera A, Rubin GJ, et al. Long-lasting T cell responses to biological warfare vaccines in human vaccines. Clin Infect Dis 2006 Jul 1;43(1):1-7 [Abstract]

Aloni-Grinstein R, Gat O, Altboum Z, et al. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun 2005 Jul;73(7):4043-53 [Abstract]

Amadi S, Dutz W, Kohout E, et al. Human anthrax in Iran: report of 300 cases and review of the literature. Tropenmed Parasitol 1974;25(1):96-104

Andrew MA, Easterling TR, Carr DB, et al. Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther 2007 Apr;81(4):547-56 [Abstract]

APIC/CDC. Bioterrorism readiness plan: a template for healthcare facilities. Apr 13, 1999 [Full text]

ASM. Sentinel laboratory guidelines for suspected agents of bioterrorism: packing and shipping infectious substances, diagnostic specimens, and biological agents. Nov 25, 2003 [Full text]

Athamna A, Athamna M, Nura A, et al. Is in vitro antibiotic combination more effective than single-drug therapy against anthrax? Antimicrob Agents Chemother 2005 Apr;49(4):1323-5 [Abstract]

Athamna A, Athamna M, Abu-Rashed N, et al. Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother 2004 Aug;54(2):424-8 [Abstract]

Avashia SB, Riggins WS, Lindley C, et al. Fatal pneumonia among metalworkers due to inhalation exposure to Bacillus cereus containing Bacillus anthracis toxin genes. Clin Infect Dis 2007 Feb 1;44(3):414-6 [Abstract]

Baggett HC, Rhodes JC, Fridkin SK, et al. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, DC, in 2001. Clin Infect Dis 2005 Oct 1;41(7):991-7 [Abstract]

Barakat LA, Quentzel HL, Jernigan JA, et al, for the Anthrax Bioterrorism Investigation Team. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002 Feb 20;287(7):863-7 [Full text]

Barrier Products, LLC. BioSeal Facility System [Home page]

Barrow EW, Dreier J, Reinelt S, et al. In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis. Antimicrob Agents Chemother 2007 Dec;51(12):4447-52 [Abstract]

Beatty ME, Ashford DA, Griffin PM, et al. Gastrointestinal anthrax: review of the literature. Arch Intern Med 2003 Nov 10;163(20):2527-31 [Abstract]

Beecher DJ. Forensic application of microbiological culture analysis to identify mail intentionally contaminated with Bacillus anthracis spores. Appl Environ Microbiol 2006 Aug;72(8):5304-10 [Abstract]

Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis 2002 Feb;8(2):222-5 [Full text]

Bhattacharjee Y, Enserink M. FBI discusses microbial forensics—but key questions still remain unanswered. Science 2008 Aug 22;321(5892):1026-7 [Full text]

Biagini RE, Sammons DL, Smith JP, et al. Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin g in serum and whole blood. Clin Vaccine Immunol 2006 May;13(5):541-6 [Abstract]

Bischof TS, Hahn BL, Sohnle PG. Characteristics of spore germination in a mouse model of cutaneous anthrax. J Infect Dis 2007 Mar 15;195(6):888-94 [Abstract]

Black DG, Taylor TM, Kerr HJ, et al. Decontamination of fluid milk containing Bacillus spores using commercial household products. J Food Prot 2008 Mar;71(3):473-8 [Abstract]

Blank S, Moskin LC, Zucker JR. An ounce of prevention is a ton of work: mass antibiotic prophylaxis for anthrax, New York City, 2001. Emerg Infect Dis 2003 Jun;9(6):615-22 [Full text]

Borio LL, Gronvall GK. Anthrax countermeasures: current status and future needs. Biosecur Bioterror 2005;3(2):102-12

Brachman PS. Anthrax. In: Warren KS, Mahmoud AF, eds. Tropical and geographic medicine. New York: McGraw-Hill, 1984:826-830

Brachman PS. Inhalation anthrax. Ann NY Acad Sci 1980;353:83-93

Brachman PS, Gold H, Plotkin SA, et al. Field evaluation of a human anthrax vaccine. Am J Public Health 1962;52:432-445

Brachman PS, Plotkin SA, Bumford FH, et al. An epidemic of inhalation anthrax: the first in the twentieth century. II. Epidemiology. Am J Hyg 1960;72:6-23

Bravata DM, Holty JE, Wang E, et al. Inhalational, gastrointestinal, and cutaneous anthrax in children. Arch Pediatr Adolesc Med 2007 Sep;161(9):896-905 [Abstract]

Bravata DM, Zaric GS, Holty JE, et al. Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies. Biosecur Bioterr 2006;4(3):244-62 [Abstract]

Brook I, Elliott TB, Pryor HI 2nd, et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 2001 Dec;18(6):559-6 [Abstract]

Brookmeyer R, Blades N. Prevention of inhalational anthrax in the US outbreak. Science 2002 Mar 8;295(5561):1861

Brookmeyer R, Blades N, Hugh-Jones M, et al. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics 2001 Jun;2(2):233-47 [Abstract]

Brouillard JE, Terriff CM, Tofan A, et al. Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents. Pharmacotherapy 2006 Jan;26(1):3-14 [Abstract]

Brown GS, Betty RG, Brockmann JE, et al. Evaluation of a wipe surface sample method for collection of Bacillus spores from nonporous surfaces. Appl Environ Microbiol 2007 Feb;73(3):706-10 [Abstract]

Canter DA. Addressing residual risk issues at anthrax cleanups: how clean is safe? J Toxicol Environ Health A 2005 Jun 11-25;68(11-12):1017-32 [Abstract]

Cavallo JD, Ramisse F, Girardet M, et al. Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000. Antimicrob Agents Chemother 2002 Jul;46(7):2307-9 [Full text]

CBC News. Saskatchewan records second human anthrax case. 2006 Aug 24 [Full text]

CDC. Acceptable biological specimens needed for testing for anthrax [Web page]

CDC. Algorithm for laboratory diagnosis of anthrax [Web page]

CDC. Anthrax: collecting, preparing, and shipping serum samples to CDC for serology testing [Full text]

CDC. Anthrax Q & A: Anthrax and animal hides [Full text]

CDC. Approved tests for the detection of Bacillus anthracis in the Laboratory Response Network [Web page]

CDC. Biosafety in microbiological and biomedical laboratories (BMBL). Ed 4, April 1999 [Full text]

CDC. Case definitions for infectious conditions under public health surveillance. MMWR 1997 May 2;46(RR10):1-55 [Full text]

CDC. CDC collaboration yields new test for anthrax. Jun 7, 2004 [Press release]

CDC. CDC responds: an update on treatment options for postal and other workers exposed to anthrax. Dec 27, 2001 [Transcript]

CDC. Clinical diagnosis and management of anthrax—lessons learned. Nov 29, 2001 [Webcast]

CDC. Comprehensive procedures for collecting environmental samples for culturing Bacillus anthracis. Apr 2002 [Full text]

CDC. Considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR 2001 Nov 9;50(44):984-6 [Full text]

CDC. Cutaneous anthrax associated with drum making using goat hides from West Africa—Connecticut, 2007. MMWR 2008 Jun 13;57(23):628-31 [Full text]

CDC. Cutaneous anthrax: recommended specimens for microbiology and pathology for diagnosis [Full text]

CDC. Facts about the laboratory response network [Full text]

CDC. FAQs about anthrax—laboratory testing [Full text]

CDC. Hand-held immunoassays for detection of Bacillus anthracis. Oct 18, 2001 [Full text]

CDC. Human anthrax associated with an epizootic among livestock—North Dakota, 2000. MMWR 2001 Aug 17;50(32):677-80 [Full text]

CDC. Inadvertent laboratory exposure to Bacillus anthracis—California 2004. MMWR 2005;54(12);301-4 [Full text]

CDC. Inhalation anthrax associated with dried animal hides: Pennsylvania and New York City, 2006. MMWR 2006 Mar 17;55(10):280-2 [Full text]

CDC. Inhalation anthrax: recommended specimens for microbiology and pathology for diagnosis [Full text]

CDC. Interim guidelines for investigation of and response to Bacillus anthracis exposures. MMWR 2001 Nov 9;50(44):987-90 [Full text]

CDC. Interim recommendations for firefighters and other first responders for the selection and use of protective clothing and respirators against biological agents [Full text]

CDC. Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR 2001 Oct 19;50(41):889-93 [Full text]

CDC. Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR 2001 Nov 2;50(43):941-8 [Full text]

CDC. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR 2001 Oct 26;50(42):909-19 [Full text].

CDC. Laboratory Response Network for bioterrorism [PowerPoint presentation]

CDC. Laboratory security and emergency response guidance for laboratories working with select agents. MMWR 2002 Dec 6;51(RR-19):1-6 [Full text]

CDC. Medical examiners, coroners, and biologic terrorism: a guidebook for surveillance and case management. MMWR 2004 Jun 11;53(RR08):1-36 [Full text]

CDC. Protecting investigators performing environmental sampling for Bacillus anthracis: personal protective equipment [Full text]

CDC. Responding to detection of aerosolized Bacillus anthracis by autonomous detection systems in the workplace. MMWR 2004 Jun 4;53(RR07):1-12 [Full text]

CDC. Select Agent Program [Web page]

CDC. Summary of notifiable diseases, United States, 1994. MMWR 1995;43(53) [Full text]

CDC. Surveillance for adverse events associated with anthrax vaccination—US Department of Defense, 1998-2000. MMWR 2000 Apr 28;49(16):341-5 [Full text]

CDC. Suspected cutaneous anthrax in a laboratory worker—Texas 2002. MMWR 2002 Apr 5;51(13):279-81 [Full text]

CDC. Syndromic surveillance: reports from a national conference, 2004. MMWR 2005 Aug 26;54(suppl) [Full text]

CDC. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR 2001 Nov 2;50(43):960 [Full text]

CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR 2002 Nov 15;51(45):1024-6 [Full text]

CDC. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR 2000 Dec 15;40(RR15):1-20 [Full text]

CDC/ASM/APHL. Basic diagnostic testing protocols for level A laboratories for the presumptive identification of Bacillus anthracis. Mar 18, 2002 [Full text]

CFIA. Anthrax—latest information. Sep 21, 2007 [Full text]

Coker PR, Smith KL, Fellows PF, et al. Bacillus anthracis virulence in guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonality. J Clin Microbiol 2003 Mar;41(3):1212-8 [Abstract]

Coker PR, Smith KL, Hugh-Jones ME. Antimicrobial susceptibilities of diverse Bacillus anthracis isolates. Antimicrob Agents Chemother 2002 Dec;46(12):3843-5 [Full text]

Coppen MJ, Noble CJ, Aubrey C. Evaluation of buffy-coat microscopy for the early diagnosis of bacteraemia. J Clin Pathol 1981 Dec;34(12):1375-7 [Full text]

Dauphin LA, Newton BR, Rasmussen MV, et al. Gamma irradiation can be used to inactivate Bacillus anthracis spores without compromising the sensitivity of diagnostic assays. Appl Environ Microbiol 2008 Jul;74(14):4427-33 [Abstract]

Davies JCA. A major epidemic of anthrax in Zimbabwe. Cent Afr J Med 1982;28:291-8

De BK, Bragg SL, Sanden GN, et al. A two-component direct fluorescent-antibody assay for rapid identification of Bacillus anthracis. Emerg Infect Dis 2002 Oct;8(10):1060-5 [Full text]

Dewan PK, Fry AM, Laserson K, et al. Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis 2002 Oct;8(10):1066-72 [Full text]

DIA. Soviet biological warfare threat. Washington, DC: US Dept of Defense, Defense Intelligence Agency, 1986. Publication DST-161OF-057-86

Dixon TC, Meselson M, Guillemin J, et al. Anthrax. N Engl J Med 1999 Sep 9:341(11):815-26 [Full text]

DoD (Department of Defense). DoD to resume anthrax vaccinations. 2006 Oct 16 [Full text]

Doganay M, Almac A, Hanagasi R. Primary throat anthrax: a report of six cases. Scand J Infect Dis 1986;18(5):415-9 [Abstract]

Doolan DL, Freilich DA, Brice GT, et al. The US Capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J Infect Dis 2007 Jan 15;195(2):174-84 [Full text]

Doust JY, Sarkarzadeh A, Kavoossi K. Corticosteriods in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest 1968 Jun;53(6):773-4

DuBois AB, Freytag LC, Clements JD. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine 2007 Jun 11;25(24):4747-54 [Abstract]

Dull PM, Wilson KE, Kournikakis B, et al. Bacillus anthracis aerosolization associated with a contaminated mail sorting machine. Emerg Infect Dis 2002 Oct;8(10):1044-7 [Full text]

Emergent BioSolutions: BioThrax Package Insert [Package insert]

Emergent BioSolutions. Sep 12, 2008 [Press release]

EPA (Environmental Protection Agency). Pesticides: Topical and chemical fact sheets: vaporized hydrogen peroxide. 2006 Nov 26 [Full text]

Fasanella A, Losito S, Adone R, et al. PCR assay to detect Bacillus anthracis spores in heat-treated specimens. J Clin Microbiol 2003 Feb;41(2):896-9 [Abstract]

FDA. Doxycycline and penicillin G procaine administration for inhalational anthrax (post-exposure). Fed Reg 2001;66-55679-82 [Full text]

FDA. Levaquin (levofloxacin) information. Mar 16, 2005; updated Jan 21, 2009 [Full text]

Fennelly KP, Davidow AL, Miller SL, et al. Airborne infection with Bacillus anthracis—from mills to mail. Emerg Infect Dis 2004 Jun:10(6):996-1001 [Full text]

Fine AM, Wong JB, Fraser HS, et al. Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses. Ann Emerg Med 2004 Mar;43(3):318-28 [Abstract]

Fitch JP, Raber E, Imbro DR. Technology challenges in responding to biological or chemical attacks in the civilian sector. Science 2003 Nov 21;302(5649):1350-4 [Abstract]

Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997 Aug 6;278(5):399-411 [Abstract]

Frawley DA, Samaan MN, Bull RL, et al. Recovery efficiencies of anthrax spores and ricin from nonporous or nonabsorbent and porous or absorbent surfaces by a variety of sampling methods. J Forensic Sci 2008 Sep;53(5):1102-7 [Abstract]

Freedman A, Afonja O, Chang MW, et al. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. JAMA 2002 Feb 20;287(7):869-74 [Full text]

GAO. Anthrax detection: DHS cannot ensure that sampling activities will be validated. GAO-07-687T. Mar 29, 2007 [Full text]

Gierczynski R, Zasada AA, Raddadi N, et al. Specific Bacillus anthracis identification by a plcR-targeted restriction site insertion-PCR (RSI-PCR) assay. FEMS Microbiol Lett 2007 Jul;272(1):55-9 [Abstract]

Giorno R, Bozue J, Cote C, et al. Morphogenesis of the Bacillus anthracis spore. J Bacteriol 2007 Feb;189(3):691-705 [Abstract]

Gladstone GP. Immunity to anthrax: protective antigen present in cell-free culture filtrates. Br J Exp Pathol 1946;27:394-418

Gold H. Anthrax: a report of one hundred seventeen cases. Arch Intern Med 1955;96:387-96

Gold JA, Hoshino Y, Hoshino S, et al. Exogenous gamma and alpha/beta interferon rescues human macrophages from cell death induced by Bacillus anthracis. Infect Immun 2004 Mar;72(3):1291-7 [Abstract]

Good KM, Houser AM, Arntzen L, et al. Naturally acquired anthrax antibodies in a cheetah (Acinonyx jubatus) in Botswana. J Wildl Dis 2008 Jul;44(3):721-3 [Abstract]

Griffith KS, Mead P, Armstrong GL, et al. Bioterrorism-related inhalational anthrax in an elderly woman, Connecticut, 2001. Emerg Infect Dis 2003 Jun;9(6):681-8 [Full text]

Guarner J, Jernigan JA, Shieh WJ, et al. Inhalational Anthrax Pathology Working Group. Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol 2003 Aug;163(2):701-9 [Abstract]

Hanna P. Anthrax pathogenesis and host response. Curr Top Microbiol Immunol 1998;225:13-35 [Abstract]

Harper B, Robinson M. Method modification (2004.08) to field testing of visible powders on a variety of nonporous environmental surfaces: field study. J AOAC Int 2006 Nov-Dec;89(6):1622-8 [Abstract]

Henderson DA. The looming threat of bioterrorism. Science 1999 Feb 26;283(5406):1279-82 [Abstract]

Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg 1956;54:28--36

HGS (Human Genome Sciences). Human Genome Sciences begins delivery of first-in-class anthrax treatment to US Strategic National Stockpile. 2009 Feb 2 [Full text]

HHS. 42 CFR Part 73: Possession, use, and transfer of select agents and toxins. Final Rule. Fed Reg 2005 Mar 18;70(52):13294-325 [Full text]

HHS. HHS to acquire anthrax immune globulin for stockpile. 2006 Jul 28 [Full text]

HHS. HHS to acquire new anthrax therapeutic treatment for stockpile. 2006 Jun 20. [Full text]

Higgins JA, Ibrahim MS, Knauert FK, et al. Sensitive and rapid identification of biological threat agents. Ann NY Acad Sci 1999; 894:130-148

Hilgren J, Swanson KM, Diez-Gonzalez F, et al. Inactivation of Bacillus anthracis spores by liquid biocides in the presence of food residue. Appl Environ Microbiol 2007 Oct;73(20):6370-7 [Abstract]

Hindson BJ, Brown SB, Marshall GD, et al. Development of an automated sample preparation module for environmental monitoring of biowarfare agents. Anal Chem 2004 Jul 1;76(13):3492-7 [Abstract]

Hoffmaster AR, Fitzgerald CC, Ribot E, et al. Molecular subtyping of Bacillus anthracis and the 2001 bioterrorism-associated anthrax outbreak, United States. Emerg Infect Dis 2002 Oct;8(10):1111-6 [Full text]

Hoffmaster AR, Meyer RF, Bowen MD, et al. Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. (Letter) Emerging Infect Dis 2002 Oct; 8(10):1178-8 [Full text]

Hoffmaster AR, Meyer RF, Bowen MD, et al. Supplement to letter above [Full text]

Hoffmaster AR, Ravel J, Rasko DA, et al. Identification of anthrax toxin genes in a Bacillus cereus associated with an illness resembling inhalation anthrax. Proc Natl Acad Sci 2004 Jun 1;101(22):8449-54 [Abstract]

Holty JE, Bravata DM, Liu H, et al. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006 Feb 21;144(4):270-80. Review [Abstract]

Holty JE, Kim RY, Bravata DM. Anthrax: a systematic review of atypical presentations. Ann Emerg Med 2006 Aug;48(2):200-11 [Abstract]

Holtz TH, Ackelsberg J, Kool JL, et al. Isolated case of bioterrorism-related inhalational anthrax, New York City, 2001. Emerg Infect Dis 2003 Jun;9(6):689-96 [Full text]

Howell JM, Mayer TA, Hanfling D, et al. Screening for inhalational anthrax due to bioterrorism: evaluating proposed screening protocols. Clin Infect Dis 2004 Dec 15;39(12):1842-7 [Full text]

Hsu VP, Lukacs SL, Handzel T, et al. Opening a Bacillus anthracis-contaminated envelope, Capitol Hill, Washington, DC: the public health response. Emerg Infect Dis 2002 Oct;8(10):1039-43 [Full text]

Hupert N, Bearman GML, Mushlin AI, et al. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med 2003 Sep 2;139(5 Pt 1):337-81 [Abstract]

Hupert N, Wattson D, Cuomo J, et al. Anticipating demand for emergency health services due to medication-related adverse events after rapid mass prophylaxis campaigns. Acad Emerg Med 2007 Mar;14(3):268-74 [Abstract]

Inglesby TV, O'Toole T, Henderson DA, et al, for the Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002 May 1;287(17):2236-52 [Full text]

Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001; epidemiologic findings. Emerg Infect Dis 2002 Oct;8(10):1019-28 [Full text]

Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001Nov-Dec;7(6):933-44 [Full text]

Kadanali A, Tasyaran MA, Kadanali S. Anthrax during pregnancy: case reports and review. Clin Infect Dis 2003 May 15;36(10):1343-6 [Abstract]

Kanafani ZA, Ghossain A, Sharara AI, et al. Endemic gastrointestinal anthrax in 1960s Lebanon: clinical manifestations and surgical findings. Emerg Infect Dis 2003 May;9(5):520-5 [Full text]

Keim P, Klevytska AM, Price LB, et al. Molecular diversity in Bacillus anthracis. J Appl Microbiol 1999 Aug; 87(2):215-7 [Abstract]

Keim P, Price LB, Klevytska AM, et al. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis. J Bacteriol 2000 May;182(10):2928-36 [Abstract]

Kenefic LJ, Beaudry J, Trim C, et al. High resolution genotyping of Bacillus anthracis outbreak strains using four highly mutable single nucleotide repeat markers. Lett Appl Microbiol 2008 May;46(5):600-3 [Abstract]

Kim W, Kim JY, Cho SL, et al. Glycosyltransferase—a specific marker for the discrimination of Bacillus anthracis from the Bacillus cereus group. J Med Microbiol 2008 Mar;57(3):279-86 [Abstract]

King D, Luna V, Cannons A, et al. Performance assessment of three commercial assays for direct detection of Bacillus anthracis spores. (Letter) J Clin Microbiol 2003 Jul;41(7):3454-5 [Full text]

Kirby JE. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect Immun 2004 Jan;72(1):430-9 [Abstract]

Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis 2003 Feb 1;36(3):328-36 [Abstract]

Kumar P, Ahuja N, Bhatnagar R. Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect Immun 2002 Sep;70(9):4997-5007 [Full text]

Kunanusont C, Limpakarnjanarat K, Foy H. Outbreak of anthrax in Thailand. Ann Trop Med Parasitol 1990 Oct:84(5):507-12 [Abstract]

Kyriacou DN, Stein AC, Yamold PR, et al. Clinical predictors of bioterrorism-related inhalational anthrax. Lancet 2004 Jul 31;364(9432):449-52 [Abstract]

Lanska DJ. Anthrax meningoencephalitis. Neurology 2002 Aug 13;59(3):327-34 [Abstract]

Leendertz FH, Ellerbrok H, Boesch C, et al. Anthrax kills wild chimpanzees in a tropical rain forest. (Letter) Nature 2004 Jul 22;430(6998):481-2 [First paragraph]

Leendertz FH, Yumlu S, Pauli G, et al. A new Bacillus anthracis found in wild chimpanzees and a gorilla from west and central Africa. PLoS Pathog 2006 Jun 21;2(1):e8 [Full text]

Lester ED, Bearman G, Ponce A. A second-generation anthrax "smoke detector." IEEE Eng Med Biol Mag 2004 Jan-Feb;23(1):130-5

Levin DB, Valadares De Amorim G. Potential for aerosol dissemination of biological weapons: lessons from biological control of insects. Biosecur Bioterror 2003 Jan;1(1):37-42

Li ZN, Mueller SN, Ye L, et al. Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity. J Virol 2005 Aug;79(15):10003-12 [Abstract]

Lawrence Livermore National Laboratory. Rapid field detection of biological agents. S&TR 2002 Jan/Feb:24-6 [Full text]

Locascio LE, Harper B, Robinson M. Standard practice for bulk sample collection and swab sample collection of visible powders suspected of being biological agents from nonporous surfaces: collaborative study. J AOAC Int 2007 Jan-Feb;90(1):299-333 [Abstract]

Lucey D. Anthrax. In: Mandell GL, Bennett JE, Dolin R: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Ed 6. Philadelphia: Elsevier Churchill Livingstone, 2005;2:3618-24

Mahlandt BG, Klein F, Lincoln RE et al. Immunologic studies of anthrax. IV. Evaluation of the immunogenicity of three components of anthrax toxin. J Immunol 1966;96:727-33

Manchee RJ, Broster MG, Stagg AJ, et al. Out of Gruinard Island. Salisbury Med Bull 1990;68(special suppl):17-8

Marano N, Plikaytis BD, Martin SW, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008 Oct 1;300(13):1532-43 [Full text]

MBAH. Minnesota experiences second largest anthrax outbreak in state history. 2006 Jul 20 [Full text]

McNeil MM, Chiang IS, Wheeling JT, et al. Short-term reactogenicity and gender effect of anthrax vaccine: analysis of a 1967-1972 study and review of the 1995-2005 medical literature. Pharmacoepidemiol Drug Saf 2007 Apr;16(3):259-74 [Abstract]

McNeil MM, Ma M, Aranas A, et al. A comparative assessment of immunization records in the Defense Medical Surveillance System and the Vaccine Adverse Event Reporting System. Vaccine 2007 Apr 30;25(17):3428-36 [Abstract]

Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994 Nov 18;266(5188):1202-8 [Abstract]

Meyer MA. Neurologic complications of anthrax: a review of the literature. Arch Neurol 2003 Apr;60(4):483-8 [Abstract]

Meyerhoff A, Albrecht R, Meyer JM, et al. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin Infect Dis 2004 Aug 1;39(3):303-8 [Abstract]

Michelow IC, Lozano J, Olsen K, et al. Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polymerase chain reaction, serological testing, and urinary antigen detection. Clin Infect Dis 2002;34:E1-11 [Abstract]

Mina B, Dym JP, Kuepper F, et al. Fatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in New York City. JAMA. 2002 Feb 20;287(7):858-62 [Full text]

Mohammed MJ, Marston CK, Popovic T, et al. Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. J Clin Microbiol 2002 Jun;40(6):1902-7 [Full text]

Monterey Institute for International Studies. Chemical and biological weapons resource page. Chemical and Biological Weapons [Web page]

Montville TJ, Dengrove R, De Siano T, et al. Thermal resistance of spores from virulent strains of Bacillus anthracis and potential surrogates. J Food Prot 2005 Nov;68(11):2362-6 [Abstract]

Mosser EM, Rest RF. The Bacillus anthracis cholesterol-dependent cytolysin, anthrolysin O, kills human neutrophils, monocytes and macrophages. BMC Microbiol 2006 Jun 21;6:56 [Full text]

Murphy D, Hull L, Horn O, et al. Anthrax vaccination in a military population before the war in Iraq: side effects and informed choice. Vaccine 2007 Nov 1;25(44):7641-8 [Abstract]

NALC (National Association of Letter Carriers). BDS technology: fact sheet [Web page]

Ndyabahinduka DGK, Chu IH, Abdou AH, et al. An outbreak of human gastrointestinal anthrax. Ann Ist Super Santa 1984;20(2-3):205-8

Nelson LS, Hanner R, Hoffman RS. Cutaneous anthrax infection (Letter) New Engl J Med 2002 Mar 21;346(12):945-6

Newcombe J, Cartwright K, Palmer WH, et al. PCR of peripheral blood for diagnosis of meningococcal disease. J Clin Microbiol 1996 Jul;34(7):1637-1640 [Full text]

Nordin JD, Goodman MJ, Kulldorff M, et al. Simulated anthrax attacks and syndromic surveillance. Emerg Infect Dis 2005 Sep;11(9):1394-8 [Full text]

OSHA. Anthrax prevention and controls [Web page]

OTA. Proliferation of weapons of mass destruction: assessing the risks. Washington, DC: US Government Printing Office, Aug 1993:553-5. Publication OTA-ISC-559 [Full text]

Payne DC, Rose CE, Kerrison J, et al. Anthrax vaccination and risk of optic neuritis in the United States military, 1998-2003. Arch Neurol 2006 Jun;63(6):871-5 [Abstract]

Perdue ML, Karns J, Higgins J, et al. Detection and fate of Bacillus anthracis (Sterne) vegetative cells and spores added to bulk tank milk. J Food Prot 2003 Dec;66(12):2349-54 [Abstract]

Peters CJ, Hartley DM. Anthrax inhalation and lethal human infection. (Letter) Lancet 2002 Feb 23;359(9307):710-1 [Full text—requires free registration]

Pfisterer RM. [An anthrax epidemic in Switzerland: clinical, diagnostic and epidemiological aspects of a mostly forgotten disease.] (Article in German) Schweiz Med Wochenschr 1991 Jun 1;12(22):813-25 [Abstract]

Pittman PR, Norris SL, Barrera Oro JG, et al. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006 Apr 24;24(17):3654-60 [Abstract]

Plotkin SA, Brachman PS, Utell M, et al. An epidemic of inhalation anthrax, the first in the twentieth century. I. Clinical features. Am J Med 1960;29:992-1001

Popov SG, Popova TG, Hopkins S, et al. Effective antiprotease-antibiotic treatment of experimental anthrax. BMC Infect Dis 2005 Apr 8;5(1):25 [Full text]

Price LB, Vogler A, Pearson T, et al. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother 2003 Jul;47(7):2362-5 [Abstract]

Quesnel-Hellmann A, Cleret A, Vidal DR, et al. Evidence for adjuvanticity of anthrax edema toxin. Vaccine 2006 Feb 6;24(6):699-702 [Abstract]

Quinn CP, Semenova VA, Elie CM, et al. Specific, sensitive, and qualitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002;8(10):1103-10 [Full text]

Rangel RA, Gonzalez DA. Bacillus anthracis meningitis. Neurology 1975;25:525-30

Rantakokko-Jalava K, Viljanen MK. Application of Bacillus anthracis PCR to simulated clinical samples. Clin Microbiol Infect 2003 Oct;9(10):1051-6 [Abstract]

Read TD, Peterson SN, Tourasse N, et al. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature 2003 May 1;423(6935):81-6 [Abstract]

Redd JT, Van Beneden C, Soter NA, et al. Performance of a rapid dermatology referral system during the anthrax outbreak. J Am Acad Dermatol 2005 Jun;52(6):1077-81 [Abstract]

Reissman DB, Whitney EA, Taylor TH Jr, et al. One-year health assessment of adult survivors of Bacillus anthracis infection. JAMA 2004 Apr 28;291(16):1994-8 [Abstract]

Rhie GE, Park YM, Han JS, et al. Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis. FEMS Immunol Med Microbiol 2005 Aug 1;45(2):341-7 [Abstract]

Rose L, Jensen B, Peterson A, et al. Swab materials and Bacillus anthracis spore recovery from nonporous surfaces. Emerg Infect Dis 2004;10(6):1023-9 [Full text]

Russell BH, Liu Q, Jenkins SA, et al. In vivo demonstration and quantification of intracellular Bacillus anthracis in lung epithelial cells. Infect Immun 2008 Sep;76(9):3975-83 [Abstract]

Ryan MAK, Smith TC, Sevick CJ, et al. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am J Epidemiol 2008 Aug 15;168(4):434-42 [Abstract]

Saggese MD, Noseda RP, Uhart MM, et al. First detection of Bacillus anthracis in feces of free-ranging raptors from central Argentina. J Wildl Dis 2007 Jan;43(1):136-41 [Abstract]

Sanderson WT, Hein MJ, Taylor L, et al. Surface sampling methods for Bacillus anthracis spore contamination. Emerg Infect Dis 2002;8(10):1145-51 [Full text]

Schmitt B, Dobrez D, Parada JP, et al. Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination. Arch Intern Med 2007 Apr 9;167(7):655-62 [Abstract]

Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis 2005 May;5(5):287-95 [Abstract]

Semenova VA, Schmidt DS, Taylor TH Jr, et al. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax. Vaccine 2007 Feb 26;25(10):1780-8 [Abstract]

Shepard CW, Soriano-Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002:8(10):1124-32 [Full text]

Shen Y, Zhukovskaya NL, Zimmer MI, et al. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc Natl Acad Sci 2004 Mar 2;101(9):3242-7 [Abstract]

Shieh WJ, Guarner J, Paddock C, et al. Anthrax Bioterrorism Investigation Team. The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax. Am J Pathol 2003 Nov;163(5):1901-10 [Abstract]

Shlyakhov E, Rubinstein E. Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Eur J Clin Microbiol Infect Dis 1996 Mar;15(3):242-5 [Abstract]

Shoop WL, Xiong Y, Wiltsie J, et al. Anthrax lethal factor inhibition. Proc Natl Acad Sci USA 2005 May 31;102(22):7958-63 [Full text]

Sirisanthana T, Brown AE. Anthrax of the gastrointestinal tract. Emerg Infect Dis 2002 Jul;8(7) [Full text]

Sirisanthana T, Navachareon N, Tharavichitkul P, et al. Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis. Am J Trop Med Hyg 1984;33(1):144-50 [Abstract]

Skottman T, Piiparinen H, Hyytiainen H, et al. Simultaneous real-time PCR detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis. Eur J Clin Microbiol Infect Dis 2007 Mar;26(3):207-11 [Abstract]

Smyth, HF. A 20 year history of anthrax in the U.S.A. In: Symposium on anthrax. Harrisburg, Pa: Department of Health, Commonwealth of Pennsylvania, Apr 1, 1941

Sneath PH, Mair NS, Sharpe ME, and Holt JG, eds. Bergey’s manual of systematic bacteriology. Vol 2. Baltimore, Md: Williams& Wilkins, 1986

Sohni Y, Kanjilal S, Kapur V. Performance evaluation of five commercial real-time PCR reagent systems using TaqMan assays for B anthracis detection. Clin Biochem 2008 May;41(7):640-4 [Abstract]

Spotts Whitney EA, Beatty ME, Taylor TH, et al. Inactivation of Bacillus anthracis spores. Emerg Infect Dis 2003 Jun;9(6):623-7 [Full text]

Stephenson J. Rapid anthrax test approved. JAMA 2004 Jul 7;292(1):30

Stern EJ, Uhde KB, Shadomy SV, et al. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis 2008 Apr;14(4):e1 [Full text]

Swartz MN. Current Concepts: Recognition and management of anthrax–an update. N Engl J Med 2001 Jun;345(22):1621-6 [Full text]

Tabatabaie P, Syadati A. Bacillus anthracis as a cause of bacterial meningitis. Pediatr Infect Dis J 1993;12(12):1035-7

Taft SC, Weiss AA. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin Vaccine Immunol 2008 Jan;15(1):71-5 [Abstract]

Takahashi H, Keim P, Kaufmann AF, et al. Bacillus anthracis incident, Kameido, Tokyo, 1993. Emerg Infect Dis 2004 Jan;10(1):117-20 [Full text]

Teshale EH, Painter J, Burr GA, et al. Environmental sampling for spores of Bacillus anthracis. Emerg Infect Dis 2002;8(10):1083-7 [Full text]

Tessier J, Green C, Padgett D, et al. Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis. Infect Immun 2007 Apr;75(4):1895-1903 [Abstract]

Tetracore, Inc [Home page]

Traeger MS, Wiersma ST, Rosenstein NE, et al. First case of bioterrorism-related inhalational anthrax in the United States, Palm Beach County, Florida, 2001. Emerg Infect Dis 2002;8(10):1029-34 [Full text]

Turnbull PCB. Guidelines for the surveillance and control of anthrax in humans and animals. Ed 3. Geneva, Switzerland: World Health Organization, Department of Communicable Disease Surveillance and Response, 1998 [Full text]

Turnbull PCB, Broster MG, Carman JA, et al. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986;52:356-63

Turnbull PCB, Sirianni NM, LeBron CI, et al. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol 2004 Aug;42(8):3626-34 [Abstract]

US Postal Service. Information on handling mail [Web page]

Vasudev M, Zacharisen MC. New-onset rheumatoid arthritis after anthrax vaccination. Ann Allergy Asthma Immunol 2006 Jan;97(1):110-2 [Abstract]

Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007 Apr 1;44(7):968-71 [Abstract]

Warfel JM, Steele AD, D’Agnillo F. Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 2005;166(6):1871-81 [Full text]

Wattiau P, Klee SR, Fretin D, et al. Occurrence and genetic diversity of Bacillus anthracis strains isolate in an active wool-cleaning factory. Appl Environ Microbiol 2008 Jul;74(13):4005-11 [Abstract]

Weber DJ, Rutala WA. Risks and prevention of nosocomial transmission of rare zoonotic diseases. Clin Infect Dis 2001;32(3):446-56 [Abstract]

Weber DJ, Rutala WA. Recognition and management of anthrax. (Letter) N Engl J Med 2002;346(12):943-6

Weber DJ, Sickbert-Bennett E, Gergen MF, et al. Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands. JAMA 2003;289(10):1274-7 [Full text]

Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Natl Acad Sci 2003 Apr 1;100(7):4346-51 [Abstract]

Wein LM. HEPA/vaccine plan for indoor anthrax remediation. Emerg Infect Dis 2005 Jan;11(1):69-76 [Full text]

Weis CP, Intrepido AJ, Miller AK, et al. Secondary aerosolization of viable Bacillus anthracis spores in a contaminated US Senate office. JAMA 2002 Dec 11;288(22):2853-8 [Full text]

Wiesen AR, Littell CT. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US army women. JAMA 2002;287(12):1556-60 [Full text]

Wilkening DA. Sverdlovsk revisited: modeling human inhalation anthrax. Proc Natl Acad Sci 2006 May 16;103(20):7589-94 [Abstract]

WHO. Guidelines for the surveillance and control of anthrax in humans and animals: bacteriology [Full text—click on text link and see Chapter 6]

WHO. Health aspects of chemical and biological weapons. Geneva, Switzerland: World Health Organization,1970:98

WHOCC. World anthrax data site [Home page]

Xu S, Labuza TP, Diez-Gonzalez F. Inactivation kinetics of avirulent Bacillus anthracis spores in milk with a combination of heat and hydrogen peroxide. J Food Prot 2008 Feb;71(2):333-8 [Abstract]

Yung PT, Lester ED, Bearman G, et al. An automated front-end monitor for anthrax surveillance systems based on the rapid detection of airborne endospores. Biotechnol Bioeng 2007 Nov 1;98(4):864-71 [Abstract]

Zeng M, Xu Q, Hesek ED, et al. N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 2006 Jan 30;24(5):662-70 [Abstract]

Back to top